| Year |
Citation |
Score |
| 2024 |
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, ... ... Arteaga CL, et al. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature Communications. 15: 2287. PMID 38480701 DOI: 10.1038/s41467-024-46495-2 |
0.411 |
|
| 2024 |
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, ... ... Arteaga CL, et al. Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF8. PMID 38433347 DOI: 10.1158/1078-0432.CCR-23-0633 |
0.341 |
|
| 2024 |
Li Z, Metzger Filho O, Viale G, dell'Orto P, Russo L, Goyette MA, Kamat A, Yardley DA, Gupta Abramson V, Arteaga CL, Spring LM, Chiotti K, Halsey C, Waks AG, King TA, et al. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial. The Journal of Clinical Investigation. PMID 38300710 DOI: 10.1172/JCI176454 |
0.381 |
|
| 2024 |
Marquez-Palencia M, Reza Herrera L, Parida PK, Ghosh S, Kim K, Das NM, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Diegeler S, Aguilera TA, Peng Y, Lewis CM, Arteaga CL, Hanker AB, et al. AXL/WRNIP1 mediates replication stress response and promotes therapy resistance and metachronous metastasis in HER2+ breast cancer. Cancer Research. PMID 38190717 DOI: 10.1158/0008-5472.CAN-23-1459 |
0.345 |
|
| 2023 |
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, ... ... Arteaga C, et al. ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology. PMID 37961351 DOI: 10.1101/2023.10.24.563645 |
0.307 |
|
| 2023 |
Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang Y, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, ... ... Arteaga C, et al. Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square. PMID 37502925 DOI: 10.21203/rs.3.rs-2966905/v1 |
0.418 |
|
| 2023 |
Marin A, Mamun AA, Patel H, Akamatsu H, Ye D, Sudhan DR, Eli L, Marcelain K, Brown BP, Meiler J, Arteaga CL, Hanker AB. Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Research. PMID 37404061 DOI: 10.1158/0008-5472.CAN-22-3617 |
0.366 |
|
| 2023 |
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Singareeka Raghavendra A, Yang-Kolodji G, Chu F, Neelapu SS, Marchese A, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research : Bcr. 25: 62. PMID 37280713 DOI: 10.1186/s13058-023-01665-w |
0.357 |
|
| 2023 |
Kumar A, Ramani V, Bharti V, de Lima Bellan D, Saleh N, Uzhachenko R, Shen C, Arteaga C, Richmond A, Reddy SM, Vilgelm A. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. Journal For Immunotherapy of Cancer. 11. PMID 37230537 DOI: 10.1136/jitc-2022-006019 |
0.321 |
|
| 2023 |
Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zwiebel J, Arnaldez FI, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, ... ... Arteaga CL, et al. Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF7. PMID 36853016 DOI: 10.1158/1078-0432.CCR-22-2150 |
0.307 |
|
| 2023 |
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Research Square. PMID 36824840 DOI: 10.21203/rs.3.rs-2388864/v1 |
0.426 |
|
| 2022 |
Gonzalez-Ericsson PI, Servetto A, Formisano L, Sánchez V, Mayer IA, Arteaga CL, Sanders ME. FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. Applied Immunohistochemistry & Molecular Morphology : Aimm. PMID 36083147 DOI: 10.1097/PAI.0000000000001058 |
0.415 |
|
| 2022 |
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, ... ... Arteaga CL, et al. Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. Jco Precision Oncology. 6: e2200165. PMID 35939768 DOI: 10.1200/PO.22.00165 |
0.347 |
|
| 2022 |
Hanna A, Nixon MJ, Estrada MV, Sanchez V, Sheng Q, Opalenik SR, Toren AL, Bauer J, Owens P, Mason FM, Cook RS, Sanders ME, Arteaga CL, Balko JM. Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. Breast Cancer Research : Bcr. 24: 51. PMID 35850776 DOI: 10.1186/s13058-022-01542-y |
0.423 |
|
| 2022 |
Liu X, Viswanadhapalli S, Kumar S, Lee TK, Moore A, Ma S, Chen L, Hsieh M, Li M, Sareddy GR, Parra K, Blatt EB, Reese TC, Zhao Y, Chang A, ... ... Arteaga CL, et al. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. Nature Cancer. PMID 35654861 DOI: 10.1038/s43018-022-00389-8 |
0.319 |
|
| 2022 |
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal of Medicine. 386: 942-950. PMID 35263519 DOI: 10.1056/NEJMoa2114663 |
0.355 |
|
| 2022 |
Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, ... ... Arteaga CL, et al. Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. Jco Precision Oncology. 6: e2100424. PMID 35138919 DOI: 10.1200/PO.21.00424 |
0.393 |
|
| 2022 |
Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, ... ... Arteaga CL, et al. Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. Cell Metabolism. 34: 90-105.e7. PMID 34986341 DOI: 10.1016/j.cmet.2021.12.001 |
0.302 |
|
| 2021 |
Servetto A, Formisano L, Arteaga CL. FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. Biochimica Et Biophysica Acta. Reviews On Cancer. 188595. PMID 34303787 DOI: 10.1016/j.bbcan.2021.188595 |
0.426 |
|
| 2021 |
Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, ... ... Arteaga CL, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. PMID 34171264 DOI: 10.1016/j.ccell.2021.06.001 |
0.376 |
|
| 2021 |
Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2100976. PMID 34092112 DOI: 10.1200/JCO.21.00976 |
0.311 |
|
| 2021 |
Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, ... Arteaga CL, et al. Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34011560 DOI: 10.1158/1078-0432.CCR-20-3905 |
0.358 |
|
| 2021 |
Metzger Filho O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discovery. PMID 33941592 DOI: 10.1158/2159-8290.CD-20-1557 |
0.4 |
|
| 2021 |
Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, Lawrence HA, Shen C, Chen SC, Ayers GD, DeNardo DG, Arteaga C, Richmond A, Vilgelm AE. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Reports. 35: 108944. PMID 33826903 DOI: 10.1016/j.celrep.2021.108944 |
0.364 |
|
| 2020 |
Garrido-Castro AC, Saura C, Barroso-Sousa R, Guo H, Ciruelos E, Bermejo B, Gavilá J, Serra V, Prat A, Paré L, Céliz P, Villagrasa P, Li Y, Savoie J, Xu Z, ... Arteaga CL, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research : Bcr. 22: 120. PMID 33138866 DOI: 10.1186/s13058-020-01354-y |
0.379 |
|
| 2020 |
Lee KM, Guerrero-Zotano AL, Servetto A, Sudhan DR, Lin CC, Formisano L, Jansen VM, González-Ericsson P, Sanders ME, Stricker TP, Raj G, Dean KM, Fiolka R, Cantley LC, Hanker AB, ... Arteaga CL, et al. Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature Communications. 11: 5488. PMID 33127913 DOI: 10.1038/s41467-020-19291-x |
0.432 |
|
| 2020 |
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, ... ... Arteaga CL, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903010. PMID 33048619 DOI: 10.1200/JCO.19.03010 |
0.309 |
|
| 2020 |
Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, ... Arteaga CL, et al. Dabrafenib and Trametinib in Patients With Tumors With Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000762. PMID 32758030 DOI: 10.1200/Jco.20.00762 |
0.373 |
|
| 2020 |
Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, ... ... Arteaga CL, et al. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902630. PMID 32463741 DOI: 10.1200/Jco.19.02630 |
0.434 |
|
| 2020 |
Hanker AB, Sudhan DR, Arteaga CL. Overcoming Endocrine Resistance in Breast Cancer. Cancer Cell. 37: 496-513. PMID 32289273 DOI: 10.1016/J.Ccell.2020.03.009 |
0.481 |
|
| 2020 |
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Delaney RJ, Hafeez A, André F, Schmid P. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer. Future Oncology (London, England). PMID 32223649 DOI: 10.2217/Fon-2020-0163 |
0.494 |
|
| 2020 |
Sudhan DR, Guerrero-Zotano A, Won H, Ericsson PG, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Brewer MR, Dugger T, Koch J, ... ... Arteaga CL, et al. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell. 37: 258-259. PMID 32049049 DOI: 10.1016/j.ccell.2020.01.010 |
0.305 |
|
| 2020 |
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, ... ... Arteaga CL, et al. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. Cancer Cell. PMID 31978326 DOI: 10.1016/J.Ccell.2019.12.013 |
0.459 |
|
| 2020 |
Johnson DB, Zhao F, Noel MS, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein L, Patton D, Williams M, Hamilton SR, Conley BA, ... Arteaga CL, et al. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31924734 DOI: 10.1158/1078-0432.Ccr-19-3443 |
0.345 |
|
| 2020 |
Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, ... ... Arteaga CL, et al. THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN. Journal of the National Cancer Institute. PMID 31922567 DOI: 10.1093/Jnci/Djz245 |
0.423 |
|
| 2020 |
Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Doyle LA, Gray RJ, Li S, McShane L, Rubinstein LV, Patton DR, Williams M, Hamilton SR, Suga JM, Conley BA, ... Arteaga CL, et al. Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. Journal of Clinical Oncology. 38: 3506-3506. DOI: 10.1200/Jco.2020.38.15_Suppl.3506 |
0.375 |
|
| 2020 |
Andre F, Su F, Solovieff N, Arteaga CL, Hortobagyi GN, Chia SKL, Neven P, Bardia A, Tripathy D, Lu Y, Wang Y, Rodriguez-Lorenc K, Taran T, Babbar N, Slamon DJ. Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. Journal of Clinical Oncology. 38: 1009-1009. DOI: 10.1200/Jco.2020.38.15_Suppl.1009 |
0.369 |
|
| 2020 |
Servetto A, Kollipara R, Formisano L, Lee K, Sudhan DR, Hanker AB, Chatterjee S, Lin A, Mendiratta S, James N, Kittler R, Arteaga CL. Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd7-04 |
0.471 |
|
| 2020 |
Kiedrowski LA, Juric D, Hardin AI, Price KS, Nagy RJ, Arteaga CL, O'Shaughnessy J, Bardia A, Cristofanilli M, Lanman RB. Abstract P4-10-15: PIK3CA mutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot-spot testing Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-10-15 |
0.384 |
|
| 2020 |
Turner NC, Krop IE, Bardia A, Damodaran S, Martin M, Benhadji KA, He Y, Ptaszynski M, Arteaga CL. Abstract OT2-07-01: A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot2-07-01 |
0.495 |
|
| 2020 |
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q, Hofsess S, Olivo M, Fabrice A, Schmid P. Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot1-07-05 |
0.47 |
|
| 2020 |
Lee K, Guerrero-Zotano A, Hanker A, Servetto A, Sudhan D, Formisano L, Jansen V, González-Ericsson P, Sanders M, Stricker T, Cantley L, Arteaga C. Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-06 |
0.505 |
|
| 2020 |
Hanker AB, Jayanthan HS, Ye D, Lin C, Akamatsu H, Sheehan JH, Koch JP, Sudhan DR, Brewer MR, Servetto A, He J, Miller VA, Lalani AS, Meiler J, Arteaga CL. Abstract GS6-04: Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs6-04 |
0.508 |
|
| 2020 |
Cleary JM, Wang V, Heist R, Kopetz S, Mitchell EP, Zwiebel J, Chen HX, Li S, Gray R, McShane L, Rubinstein L, Patton D, Meric-Bernstam F, Dillmon M, Williams M, ... ... Arteaga C, et al. Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct061 |
0.4 |
|
| 2020 |
Akamatsu H, Mino R, Mettlen M, Ye D, Sudhan DR, Lin A, Marin A, Servetto A, Lee K, Chatterjee S, Schmid SL, Arteaga CL, Hanker AB. Abstract 3675: HER2 missense mutations in breast cancer cells do not alter HER2 internalization or sensitivity to T-DM1 Cancer Research. 80: 3675-3675. DOI: 10.1158/1538-7445.Am2020-3675 |
0.493 |
|
| 2019 |
Viswanadhapalli S, Ma S, Sareddy GR, Lee TK, Li M, Gilbreath C, Liu X, Luo Y, Pratap UP, Zhou M, Blatt EB, Kassees K, Arteaga C, Alluri P, Rao M, et al. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers. Breast Cancer Research : Bcr. 21: 150. PMID 31878959 DOI: 10.1186/S13058-019-1227-8 |
0.459 |
|
| 2019 |
Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Research : Bcr. 21: 146. PMID 31852484 DOI: 10.1186/S13058-019-1230-0 |
0.531 |
|
| 2019 |
Lehmann BD, Abramson VG, Sanders M, Mayer EL, Haddad T, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, ... Arteaga CL, et al. TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31822498 DOI: 10.1158/1078-0432.Ccr-19-2170 |
0.439 |
|
| 2019 |
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sorensen M, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery. PMID 31806627 DOI: 10.1158/2159-8290.Cd-19-0966 |
0.537 |
|
| 2019 |
Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, ... ... Arteaga CL, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900818. PMID 31765263 DOI: 10.1200/Jco.19.00818 |
0.429 |
|
| 2019 |
Nixon MJ, Formisano L, Mayer IA, Estrada MV, González-Ericsson PI, Isakoff SJ, Forero-Torres A, Won H, Sanders ME, Solit DB, Berger MF, Cantley LC, Winer EP, Arteaga CL, Balko JM. PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer. 5: 31. PMID 31552290 DOI: 10.1038/s41523-019-0126-6 |
0.447 |
|
| 2019 |
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, ... Arteaga CL, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31504139 DOI: 10.1093/Annonc/Mdz291 |
0.449 |
|
| 2019 |
Unni N, Arteaga CL. Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer? Jama Oncology. PMID 31465107 DOI: 10.1001/Jamaoncol.2019.2525 |
0.365 |
|
| 2019 |
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31407010 DOI: 10.1093/annonc/mdz215 |
0.325 |
|
| 2019 |
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, ... ... Arteaga CL, et al. FGFR1 gene amplification mediates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor positive (HR+) breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31371343 DOI: 10.1158/1078-0432.Ccr-19-0138 |
0.48 |
|
| 2019 |
Chakrabarty A, Surendran S, Bhola NE, Mishra VS, Wani TH, Baghel KS, Arteaga CL, Garg R, Chowdhury G. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells. Carcinogenesis. PMID 31219154 DOI: 10.1093/Carcin/Bgz118 |
0.5 |
|
| 2019 |
Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook R, ... ... Arteaga CL, et al. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors that Demonstrate in vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of Medicinal Chemistry. PMID 30929420 DOI: 10.2210/Pdb6Ne5/Pdb |
0.476 |
|
| 2019 |
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, ... ... Arteaga CL, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature Communications. 10: 1373. PMID 30914635 DOI: 10.1038/S41467-019-09068-2 |
0.532 |
|
| 2019 |
Hanker AB, Kaklamani V, Arteaga CL. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discovery. PMID 30867161 DOI: 10.1158/2159-8290.Cd-18-1175 |
0.425 |
|
| 2019 |
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, ... ... Arteaga CL, et al. Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1437. PMID 30770496 DOI: 10.1158/1078-0432.Ccr-18-4264 |
0.37 |
|
| 2019 |
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, ... ... Arteaga CL, et al. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1434. PMID 30770493 DOI: 10.1158/1078-0432.CCR-18-4267 |
0.381 |
|
| 2019 |
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, ... ... Arteaga CL, et al. Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1433. PMID 30770492 DOI: 10.1158/1078-0432.CCR-18-4268 |
0.317 |
|
| 2019 |
Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, ... ... Arteaga CL, et al. Correction: ER Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1431. PMID 30770490 DOI: 10.1158/1078-0432.CCR-18-4270 |
0.328 |
|
| 2019 |
Unni N, Sudhan DR, Arteaga CL. Correction: Neratinib: Inching Up on the Cure Rate of HER2 Breast Cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1430. PMID 30770489 DOI: 10.1158/1078-0432.Ccr-18-4271 |
0.318 |
|
| 2019 |
Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research. 79: 876. PMID 30770371 DOI: 10.1158/0008-5472.Can-18-4088 |
0.415 |
|
| 2019 |
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. Cancer Research. 79: 875. PMID 30770370 DOI: 10.1158/0008-5472.CAN-18-4087 |
0.343 |
|
| 2019 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, ... ... Arteaga CL, et al. Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research. 79: 874. PMID 30770369 DOI: 10.1158/0008-5472.Can-18-4086 |
0.42 |
|
| 2019 |
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL. Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer. Cancer Research. 79: 873. PMID 30770368 DOI: 10.1158/0008-5472.CAN-18-4085 |
0.372 |
|
| 2019 |
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, ... ... Arteaga CL, et al. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. PMID 30755741 DOI: 10.1038/S41586-019-0974-0 |
0.378 |
|
| 2019 |
Guerrero-Zotano AL, Arteaga CL. Correction: Neoadjuvant Trials in ER Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discovery. 9: 304. PMID 30737218 DOI: 10.1158/2159-8290.Cd-18-1516 |
0.327 |
|
| 2019 |
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, ... ... Arteaga CL, et al. Correction: An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. 9: 303. PMID 30737217 DOI: 10.1158/2159-8290.Cd-18-1515 |
0.445 |
|
| 2019 |
Mayer IA, Prat A, Egle D, Blau S, Perez Fidalgo JA, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz SA, Garcia Estevez L, van Dam PA, Kümmel S, ... ... Arteaga CL, et al. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30723140 DOI: 10.1158/1078-0432.Ccr-18-3160 |
0.475 |
|
| 2019 |
Kaklamani VG, Richardson AL, Arteaga CL. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. The Oncologist. PMID 30651399 DOI: 10.1634/Theoncologist.2018-0314 |
0.503 |
|
| 2019 |
Hoste G, Slembrouck L, Jongen L, Punie K, Matton T, Vander Borght S, Vanden Bempt I, Menten J, Wildiers H, Floris G, Arteaga C, Neven P. Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Clinical Drug Investigation. 39: 113. PMID 30637612 DOI: 10.1007/S40261-019-00748-X |
0.452 |
|
| 2019 |
Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, ... ... Arteaga CL, et al. Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 8. PMID 30614786 DOI: 10.7554/Elife.44851 |
0.443 |
|
| 2019 |
Metzger Filho O, Viale G, Trippa L, Li T, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring L, Waks AG, Janiszewska M, Wrabel E, Demeo M, Bardia A, King TA, et al. HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Journal of Clinical Oncology. 37: 502-502. DOI: 10.1200/Jco.2019.37.15_Suppl.502 |
0.452 |
|
| 2019 |
Salama AK, Li S, Macrae ER, Park J, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane L, Rubinstein L, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, ... Arteaga CL, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Journal of Clinical Oncology. 37: 3002-3002. DOI: 10.1200/Jco.2019.37.15_Suppl.3002 |
0.33 |
|
| 2019 |
Viswanadhapalli S, Ma S, Lee T, Sareddy G, Liu X, Ekoue D, Alluri A, Luo Y, Kassees K, Arteaga C, Alluri P, Weintraub S, Tekmal R, Ahn J, Raj G, et al. Abstract P5-04-23: Enhancing the activity of a novel estrogen receptor coregulator binding modulator (ERX-11) against ER-positive therapy resistant breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-04-23 |
0.449 |
|
| 2019 |
Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zweibel J, Arnaldez FI, McShane LM, Li S, Gray RJ, Rubenstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, ... ... Arteaga CL, et al. Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-010 |
0.302 |
|
| 2019 |
Won HH, Selcuklu SD, Piha-Paul SA, Saura C, Rodon J, Mayer IA, Loi S, Shapiro GI, Lu J, Brufsky A, Zimel C, Melcer M, Scaltriti M, Eli LD, Cutler RE, ... ... Arteaga C, et al. Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-929 |
0.369 |
|
| 2019 |
Servetto A, Formisano L, Kollipara R, Sudhan DR, Lee K, Chatterjee S, Hanker AB, Mendiratta S, Kittler R, Arteaga CL. Abstract 4402: FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4402 |
0.445 |
|
| 2019 |
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow J, Gray RJ, McShane LM, Rubenstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, ... Arteaga CL, et al. Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct139 |
0.426 |
|
| 2019 |
Kummar S, Li S, Reiss K, Ford JM, Mitchell EP, Zwiebel JA, Takebe N, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Brufsky A, Conley BA, ... Arteaga CL, et al. Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct138 |
0.492 |
|
| 2019 |
Sudhan DR, Hanker AB, Guerrero-Zotano A, Formisano L, Guo Y, Liu Q, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Abstract 1828: Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers Cancer Research. 78: 1828-1828. DOI: 10.1158/1538-7445.Am2018-1828 |
0.459 |
|
| 2019 |
Chen AP, Li S, Coffey B, Tricoli JV, Hamilton SR, Williams MP, Mitchell EP, Patton D, Gray RJ, McShane LM, Rubinstein LV, Arteaga CL, O'Dwyer PJ, Harris LN, Conley BA, et al. Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131) Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A089 |
0.323 |
|
| 2019 |
Harris LN, Gray RJ, Conley BA, Chen AP, Flaherty KT, Hamilton SR, Williams PM, Karlovich C, Patton D, Li S, McShane LM, Rubinstein LV, Mitchell EP, Tricoli JV, Little RF, ... Arteaga CL, et al. Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A079 |
0.373 |
|
| 2018 |
Janku F, Jegede O, Puhalla SL, Konstantinopoulos P, Meric-Bernstam F, Mitchell EP, Zwiebel JA, McShane LM, Li S, Rubinstein LV, Doyle LA, Patton D, Conley BA, O'Dwyer PJ, Harris LN, ... Arteaga C, et al. NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii137. PMID 32136211 DOI: 10.1093/Annonc/Mdy279.406 |
0.367 |
|
| 2018 |
Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, ... Arteaga CL, et al. Combined blockade of activating mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30314968 DOI: 10.1158/1078-0432.Ccr-18-1544 |
0.46 |
|
| 2018 |
Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, Gonzalez-Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30274983 DOI: 10.1158/1078-0432.Ccr-18-1131 |
0.461 |
|
| 2018 |
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer (Oxford, England : 1990). 103: 147-154. PMID 30241001 DOI: 10.1016/j.ejca.2018.08.002 |
0.373 |
|
| 2018 |
Garrett JT, Chakrabarty A, Arteaga CL. Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 9: 32400. PMID 30190795 DOI: 10.18632/Oncotarget.26017 |
0.37 |
|
| 2018 |
Hoste G, Slembrouck L, Jongen L, Punie K, Matton T, Vander Borght S, Vanden Bempt I, Menten J, Wildiers H, Floris G, Arteaga C, Neven P. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. Clinical Drug Investigation. 38: 1071-1075. PMID 30187361 DOI: 10.1007/S40261-018-0696-3 |
0.451 |
|
| 2018 |
Zonneville J, Safina A, Truskinovsky AM, Arteaga CL, Bakin AV. TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. Bmc Cancer. 18: 670. PMID 29921235 DOI: 10.1186/S12885-018-4587-Z |
0.374 |
|
| 2018 |
Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 7: e1438106. PMID 29872580 DOI: 10.1080/2162402X.2018.1438106 |
0.317 |
|
| 2018 |
Unni N, Sudhan DR, Arteaga CL. Neratinib: Inching up on the cure rate of HER2+ breast cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29802101 DOI: 10.1158/1078-0432.Ccr-18-1114 |
0.492 |
|
| 2018 |
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29718092 DOI: 10.1093/Annonc/Mdy155 |
0.455 |
|
| 2018 |
Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Pérez-Fidalgo JA, Lluch A, Llombart-Cussac A, ... ... Arteaga CL, et al. ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29581135 DOI: 10.1158/1078-0432.Ccr-17-2904 |
0.457 |
|
| 2018 |
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, ... ... Arteaga CL, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 554: 189-194. PMID 29420467 DOI: 10.1038/Nature25475 |
0.453 |
|
| 2018 |
Chae YK, Vaklavas C, Cheng HH, Hong F, Harris L, Mitchell EP, Zwiebel JA, McShane L, Gray RJ, Li S, Ivy SP, Ansher SS, Hamilton SR, Williams PM, Tricoli JV, ... Arteaga CL, et al. Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. Journal of Clinical Oncology. 36: 2503-2503. DOI: 10.1200/Jco.2018.36.15_Suppl.2503 |
0.458 |
|
| 2018 |
Hortobagyi GN, Paluch-Shimon S, Petrakova K, Villanueva C, Chan A, Nusch A, Yap YS, Hart L, Favret A, Marschner N, Sonke GS, Oma Ohnstad H, Arteaga C, Su F, He W, et al. First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses. Journal of Clinical Oncology. 36: 1022-1022. DOI: 10.1200/Jco.2018.36.15_Suppl.1022 |
0.408 |
|
| 2018 |
Krop IE, Jegede O, Grilley-Olson JE, Lauring JD, Hamilton SR, Zwiebel JA, Li S, Rubinstein L, Doyle A, Patton DR, Mitchell EP, Arteaga CL, Conley BA, Sims D, Harris L, et al. Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. Journal of Clinical Oncology. 36: 101-101. DOI: 10.1200/Jco.2018.36.15_Suppl.101 |
0.355 |
|
| 2018 |
Jhaveri KL, Makker V, Wang XV, Chen AP, Flaherty K, Conley BA, O'Dwyer PJ, Williams PM, Hamilton SR, Harris L, McShane L, Rubinstein L, Gray RJ, Li S, Mitchell EP, ... ... Arteaga CL, et al. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. Journal of Clinical Oncology. 36: 100-100. DOI: 10.1200/Jco.2018.36.15_Suppl.100 |
0.426 |
|
| 2018 |
Croessmann S, Formisano L, Dugger T, Avogadri-Connors F, Cutler RE, Lalani AS, Arteaga CL. Abstract 4008: Activating HER2 (ERBB2) mutations lead to endocrine therapy resistance through S6K activation Cancer Research. 78: 4008-4008. DOI: 10.1158/1538-7445.Am2018-4008 |
0.514 |
|
| 2018 |
Nixon MJ, Estrada VM, Opalenki SR, Hicks D, Korrer M, Sanders ME, Salgado R, Kim Y, Cook R, Arteaga CL, Balko JM. Abstract 2982: Somatic TP53 mutations alter the immune microenvironmentafter chemotherapy in breast cancer Immunology. DOI: 10.1158/1538-7445.Am2018-2982 |
0.42 |
|
| 2018 |
Chen AP, O'Dwyer PJ, Harris L, Conley BA, Hamilton SR, Williams M, Gray RJ, Li S, McShane LM, Rubinstein LV, Lee SI, Kumar S, Mitchell EP, Zwiebel JA, Gatsonis CA, ... ... Arteaga CL, et al. Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Pl03-01 |
0.381 |
|
| 2017 |
Croessmann S, Sheehan JH, Lee KM, Sliwoski GR, He J, Nagy RJ, Riddle DA, Mayer IA, Balko JM, Lanman RB, Miller V, Cantley LC, Meiler J, Arteaga CL. PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3Kα inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29284706 DOI: 10.1158/1078-0432.Ccr-17-2141 |
0.344 |
|
| 2017 |
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Targeted Oncology. PMID 29218624 DOI: 10.1007/S11523-017-0542-1 |
0.436 |
|
| 2017 |
O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. PMID 29164421 DOI: 10.1007/S10549-017-4518-8 |
0.445 |
|
| 2017 |
Abramson RG, Lakomkin N, Hainline A, Kang H, Hutson MS, Arteaga CL. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival. Ajr. American Journal of Roentgenology. W1-W7. PMID 29064750 DOI: 10.2214/Ajr.17.18249 |
0.415 |
|
| 2017 |
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, ... Arteaga CL, et al. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Journal of the National Cancer Institute. 109. PMID 29059433 DOI: 10.1093/Jnci/Djx065 |
0.424 |
|
| 2017 |
Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, ... ... Arteaga CL, et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism. 26: 633-647.e7. PMID 28978427 DOI: 10.1016/J.Cmet.2017.09.009 |
0.404 |
|
| 2017 |
Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AV. Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget. 8: 61969-61981. PMID 28977919 DOI: 10.18632/Oncotarget.18755 |
0.502 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, ... ... Arteaga CL, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.518 |
|
| 2017 |
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, ... ... Arteaga CL, et al. Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28751448 DOI: 10.1158/1078-0432.Ccr-17-1232 |
0.52 |
|
| 2017 |
Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AV. Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget. PMID 28706147 DOI: 10.18632/oncotarget.18755 |
0.405 |
|
| 2017 |
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 28576675 DOI: 10.1016/S1470-2045(17)30376-5 |
0.505 |
|
| 2017 |
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, ... ... Arteaga CL, et al. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine. 9. PMID 28539475 DOI: 10.1126/Scitranslmed.Aal4682 |
0.447 |
|
| 2017 |
Guerrero-Zotano AL, Arteaga CL. Neoadjuvant Trials in ER(+) Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discovery. PMID 28495849 DOI: 10.1158/2159-8290.Cd-17-0228 |
0.452 |
|
| 2017 |
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Gianni L, Koch JP, Tyson DR, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker T, Arteaga CL. Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2+ breast cancer. Cancer Research. PMID 28396358 DOI: 10.1158/0008-5472.Can-16-2808 |
0.456 |
|
| 2017 |
Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, ... ... Arteaga CL, et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28381415 DOI: 10.1158/1078-0432.Ccr-16-2287 |
0.527 |
|
| 2017 |
Hanker AB, Red Brewer M, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, ... ... Arteaga CL, et al. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. Cancer Discovery. PMID 28274957 DOI: 10.1158/2159-8290.Cd-16-1431 |
0.497 |
|
| 2017 |
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders M, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KN, Sanchez V, Rosenbluth JM, Dillon PM, Forrero-Torres A, ... ... Arteaga CL, et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28270498 DOI: 10.1158/1078-0432.Ccr-16-3055 |
0.446 |
|
| 2017 |
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sanchez V, Ericsson PG, Sanders M, Pohlmann PR, Pishvaian MJ, Riddle DA, ... ... Arteaga CL, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Research. PMID 28249908 DOI: 10.1158/0008-5472.Can-16-2653 |
0.424 |
|
| 2017 |
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms Tumors. Molecular Oncology. PMID 28188683 DOI: 10.1002/1878-0261.12044 |
0.401 |
|
| 2017 |
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte PF, Arteaga CL, Cameron DA, et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Journal of Clinical Oncology. 35: 1038-1038. DOI: 10.1200/Jco.2017.35.15_Suppl.1038 |
0.335 |
|
| 2017 |
O'Shaughnessy J, Petrakova K, Sonke G, André F, Conte P, Arteaga C, Cameron D, Hart L, Villanueva C, Jakobsen E, Lindquist D, Souami F, Li X, Germa C, Hirawat S, et al. Abstract P4-22-05: First-line ribociclib plus letrozole in patients withde novoHR+, HER2– advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-22-05 |
0.435 |
|
| 2017 |
Andre F, Stemmer SM, Campone M, Petrakova K, Paluch-Shimon S, Yap Y, Marschner N, Chan A, Villanueva C, Hart LL, Arteaga CL, Sonke GS, Grischke E, Alba E, Nusch A, et al. Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct045 |
0.481 |
|
| 2017 |
O'Regan R, Arteaga CL, Bachelot T, Ciruelos E, Lønning PE, Sankaran B, Wang YA, Scheuer N, Sellami D, Hirawat S, Leo AD. Abstract CT010: Efficacy results based onPIK3CAstatus in BELLE-3: A Phase 3 study of buparlisib (BKM120) + fulvestrant in postmenopausal women with aromatase inhibitor-treated, HR+/HER2- ABC after progression on an mTOR inhibitor Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct010 |
0.449 |
|
| 2017 |
Hyman DM, Piha-Paul SA, Rodon J, Saura C, Shapiro GI, Quinn DI, Moreno V, Mayer IA, Arteaga C, Boni V, Calvo E, Loi S, Lockhart AC, Smyth LM, Erinjeri J, et al. Abstract CT001: Neratinib inHER2orHER3mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct001 |
0.479 |
|
| 2017 |
Ferraro GB, Kodack DP, Askoxylakis V, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao AZ, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, ... ... Arteaga CL, et al. Abstract 5008: The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation Cancer Research. 77: 5008-5008. DOI: 10.1158/1538-7445.Am2017-5008 |
0.459 |
|
| 2017 |
Schwarz LJ, Croessmann SE, Avogadri-Connors F, Cutler RE, Lalani AS, Arteaga CL. Abstract 4818: Neratinib/fulvestrant but not fulvestrant alone maintain complete responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+ xenografts Cancer Research. 77: 4818-4818. DOI: 10.1158/1538-7445.Am2017-4818 |
0.417 |
|
| 2017 |
Lee K, Giltnane J, Balko J, Schwarz L, Guerrero A, Hutchinson K, Hicks M, Sanchez V, Sanders M, Lee T, Olejniczak E, Fesik S, Arteaga C. Abstract 3890: Mitochondrial MCL1 maintains triple negative breast cancer stem cells and contributes to chemotherapy resistance Cancer Research. 77: 3890-3890. DOI: 10.1158/1538-7445.Am2017-3890 |
0.456 |
|
| 2017 |
Conte P, Paluch-Shimon S, Burris H, Petrakova K, Blackwell K, Dittrich C, Arteaga C, Sutradhar S, Miller M, Campone M. First-line ribociclib + letrozole in patients with HR+, HER2–advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial The Breast. 32: S70. DOI: 10.1016/S0960-9776(17)30236-9 |
0.424 |
|
| 2016 |
Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney S, Chau NG, Cho DC, Lager JJ, Pearlberg J, Shapiro GI, Arteaga CL. Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3 neutralizing human antibody SAR256212 in patients with solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28031425 DOI: 10.1158/1078-0432.Ccr-16-1764 |
0.354 |
|
| 2016 |
Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Reviews. PMID 27896521 DOI: 10.1007/S10555-016-9637-X |
0.495 |
|
| 2016 |
Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer. Breast Cancer Research and Treatment. PMID 27771839 DOI: 10.1007/S10549-016-4011-9 |
0.51 |
|
| 2016 |
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England Journal of Medicine. PMID 27717303 DOI: 10.1056/Nejmoa1609709 |
0.412 |
|
| 2016 |
Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, ... ... Arteaga CL, et al. The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. Elife. 5. PMID 27410477 DOI: 10.7554/Elife.15828 |
0.518 |
|
| 2016 |
Mayer IA, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders M, Juric D, Solit D, Berger MF, Won H, Li Y, Cantley LC, Winer EP, Arteaga CL. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27126994 DOI: 10.1158/1078-0432.Ccr-16-0134 |
0.509 |
|
| 2016 |
Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, ... ... Arteaga CL, et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine. 8: 334ra53. PMID 27075627 DOI: 10.1126/Scitranslmed.Aad3001 |
0.549 |
|
| 2016 |
Jansen VM, Mayer IA, Arteaga CL. Is There a Future for AKT Inhibitors in the Treatment of Cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 2599-601. PMID 26979397 DOI: 10.1158/1078-0432.Ccr-16-0100 |
0.492 |
|
| 2016 |
Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine. 67: 11-28. PMID 26473415 DOI: 10.1146/Annurev-Med-062913-051343 |
0.447 |
|
| 2016 |
Skala MC, Walsh AJ, Shah AT, Sharick JT, Heaster TM, Cook RS, Arteaga CL, Sanders ME, Meszoely I. Imaging cellular metabolic heterogeneity in cancer Cancer. DOI: 10.1364/Cancer.2016.Jw4A.1 |
0.326 |
|
| 2016 |
Conley BA, Chen AP, O'Dwyer PJ, Arteaga CL, Hamilton SR, Williams PM, Little RF, Takebe N, Patton D, Sazali K, Zhang J, Zwiebel JA, Mitchell EP, Gray RJ, McShane L, et al. NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2606 |
0.349 |
|
| 2016 |
Rioth MJ, Arteaga CL, Warner J. Sequencing of advanced breast cancers to reveal an evolving genetic landscape. Journal of Clinical Oncology. 34: 11514-11514. DOI: 10.1200/Jco.2016.34.15_Suppl.11514 |
0.428 |
|
| 2016 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Weigelt B, Sakr RA, King TA, Chandarlapaty S, Reis-Filho JS, Hanker AB, Arteaga CL, Yeon PS, Michor F, Polyak K. Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Pr05 |
0.453 |
|
| 2016 |
Conley BA, Gray R, Chen A, O’Dwyer P, Arteaga C, Coffey B, Patton D, Li S, McShane LM, Rubinstein L, Comis R, Abrams J, Williams PM, Lih C, Hamilton S, et al. Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct101 |
0.401 |
|
| 2016 |
Guerrero-Zotano A, Stricker T, Hutchinson KE, Formisano L, Giltnane J, Ruiz A, Arteaga CL. Abstract 4508: Genomic profiling of ER+ breast cancers treated with prolonged neoadjuvant letrozole reveal a high frequency of NOTCH2 mutations in clinically resistant tumors Cancer Research. 76: 4508-4508. DOI: 10.1158/1538-7445.Am2016-4508 |
0.468 |
|
| 2016 |
Lee K, Giltnane J, Balko J, Arteaga C. Abstract 3328: MYC and MCL1 cooperatively promote chemotherapy-resistant cancer stem cells through regulation of mitochondrial biogenesis and oxidative phosphorylation Cancer Research. 76: 3328-3328. DOI: 10.1158/1538-7445.Am2016-3328 |
0.387 |
|
| 2016 |
Hanker AB, Estrada MV, Zhao J, Cheng F, Moore PD, Tyson D, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker TP, Arteaga CL. Abstract 302: ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer Cancer Research. 76: 302-302. DOI: 10.1158/1538-7445.Am2016-302 |
0.499 |
|
| 2016 |
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, Campone M, Blackwell K, André F, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, et al. breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC) Annals of Oncology. 27: vi553. DOI: 10.1093/Annonc/Mdw435.03 |
0.455 |
|
| 2015 |
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CL. Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population. Cancer Research. PMID 26676751 DOI: 10.1158/0008-5472.Can-15-1640-T |
0.475 |
|
| 2015 |
Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao Z. Systematic prioritization of druggable mutations in ~5,000 genomes across 16 cancer types using a structural genomics-based approach. Molecular & Cellular Proteomics : McP. PMID 26657081 DOI: 10.1074/Mcp.M115.053199 |
0.347 |
|
| 2015 |
Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 132: 2248-58. PMID 26644247 DOI: 10.1161/Circulationaha.115.010484 |
0.396 |
|
| 2015 |
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. PMID 26640141 DOI: 10.1038/Onc.2015.377 |
0.544 |
|
| 2015 |
Young CD, Arteaga CL, Cook RS. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Research : Bcr. 17: 148. PMID 26637440 DOI: 10.1186/S13058-015-0656-2 |
0.543 |
|
| 2015 |
Stricker T, Arteaga CL. Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy. Cancer Discovery. 5: 1124-6. PMID 26526693 DOI: 10.1158/2159-8290.Cd-15-1166 |
0.335 |
|
| 2015 |
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sanchez V, Sanders M, Cook RS, Pilkinton MA, Mallal SA, ... ... Arteaga CL, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26515496 DOI: 10.1158/1078-0432.Ccr-15-1125 |
0.459 |
|
| 2015 |
Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, ... ... Arteaga CL, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America. PMID 26508629 DOI: 10.1073/Pnas.1516853112 |
0.416 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics. 47: 1212-9. PMID 26301495 DOI: 10.1038/Ng.3391 |
0.39 |
|
| 2015 |
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, et al. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26169615 DOI: 10.1200/Jco.2014.60.0353 |
0.38 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, ... ... Arteaga CL, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.489 |
|
| 2015 |
Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. Journal of Biomedical Optics. 20: 26004. PMID 25700233 DOI: 10.1117/1.Jbo.20.2.026004 |
0.411 |
|
| 2015 |
Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Research. 75: 405-14. PMID 25480943 DOI: 10.1158/0008-5472.Can-14-2475 |
0.495 |
|
| 2015 |
Ju JH, Oh S, Lee KM, Yang W, Nam KS, Moon HG, Noh DY, Kim CG, Park G, Park JB, Lee T, Arteaga CL, Shin I. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes. Cell Death and Differentiation. 22: 665-76. PMID 25342465 DOI: 10.1038/Cdd.2014.155 |
0.446 |
|
| 2015 |
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 34: 3968-76. PMID 25284585 DOI: 10.1038/Onc.2014.328 |
0.526 |
|
| 2015 |
Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TE. Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 119-28. PMID 25034624 DOI: 10.1007/S11307-014-0770-Z |
0.32 |
|
| 2015 |
Pinto JA, Araujo J, Cardenas NK, Balko JM, Arteaga CL, Gomez H. A 3-gene expression score as prognostic factor in triple negative and basal breast tumors with residual disease. Journal of Clinical Oncology. 33: 1097-1097. DOI: 10.1200/Jco.2015.33.15_Suppl.1097 |
0.41 |
|
| 2015 |
Lu Y, Fry W, Bauer JA, Arteaga CL. Abstract A2-15: Gain-of-function kinase library screen identifies mechanisms of resistance to antiestrogen therapies in ER+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A2-15 |
0.528 |
|
| 2015 |
Balko JM, Denkert C, Salgado R, O'Hely M, Savas P, Beavis PA, Darcy PK, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sanders ME, Cook RS, Wang K, Miller VA, ... ... Arteaga CL, et al. Abstract S1-08: Reduced tumor lymphocytic infiltration in the residual disease (RD) of post-neoadjuvant chemotherapy (NAC) triple-negative breast cancers (TNBC) is associated with Ras/MAPK activation and poorer survival Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S1-08 |
0.445 |
|
| 2015 |
Giltnane JM, Balko JM, Stricker TL, Young C, Estrada MV, Wagle N, Allen Ev, Mu XJ, Sanchez V, Farley J, Fitzgerald K, Graber A, Pinto JA, Doimi F, Gómez H, ... ... Arteaga CL, et al. Abstract PD6-3: Recurrent ESR1 fusion transcripts are associated with endocrine resistance in estrogen receptor positive, HER2 negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-3 |
0.484 |
|
| 2015 |
Schwarz LJ, Balko JM, Giltnane JM, Estrada MV, Sanders ME, Wang K, Lin NU, Miller VA, Stephens P, Yelensky R, Pinto JA, Gómez HL, Landis MD, Chang JC, Arteaga CL. Abstract P6-03-03: Enrichment of janus kinase-2 (JAK2)-amplified tumor cell populations in triple-negative breast cancers (TNBC) during chemotherapy treatment Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-03-03 |
0.466 |
|
| 2015 |
Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC. Abstract P3-06-38: Optical metabolic imaging predicts therapeutic response in breast cancer tumors and organoids Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-38 |
0.464 |
|
| 2015 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. Abstract P3-04-03: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-04-03 |
0.51 |
|
| 2015 |
Bardia A, Dickler MN, Mayer IA, Winer EP, Mahmood U, Ulaner G, Manning HC, Rix P, Hager JH, Roychowdhury D, Maneval EC, Arteaga CL, Baselga J. Abstract P1-13-01: Phase I study of ARN-810, a novel and potent oral selective estrogen receptor degrader, in postmenopausal women with metastatic estrogen receptor positive (ER+), HER2- breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-13-01 |
0.484 |
|
| 2015 |
Abu-Khalaf M, Mayer I, Litten JB, Raponi M, Allen AR, Pusztai L, Arteaga CL. Abstract OT1-1-13: A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathway Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Ot1-1-13 |
0.492 |
|
| 2015 |
Young CD, Koch JP, Cook RS, Arteaga CL. Abstract LB-012: Inhibition of PI3K induces paracrine factors, which promote growth and survival of human breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-012 |
0.473 |
|
| 2015 |
Mayer IA, Abramson V, Balko J, Sanders M, Juric D, Solit D, Li Y, Cantley L, Winer E, Arteaga C. Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct232 |
0.445 |
|
| 2015 |
Dickler M, Bardia A, Mayer I, Winer E, Rix P, Hager J, Chen M, Chan I, Chow-Maneval E, Arteaga C, Baselga J. Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct231 |
0.454 |
|
| 2015 |
Bhola NE, Jansen VM, Arteaga CL. Abstract 4240: TORC inhibition enriches for a cancer stem cell-like population with FGFR-dependent Notch1 activation Cancer Research. 75: 4240-4240. DOI: 10.1158/1538-7445.Am2015-4240 |
0.358 |
|
| 2015 |
Jansen VM, Bhola NE, Bauer JA, Arteaga CL. Abstract 2844: RNA interference kinome-wide screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition ER-positive breast cancer Cancer Research. 75: 2844-2844. DOI: 10.1158/1538-7445.Am2015-2844 |
0.502 |
|
| 2015 |
Formisano L, Young CD, Bhola N, Giltnane JM, Estrada MV, Arteaga CL. Abstract 2435: FGFR1 is associated with resistance to interaction with estrogen receptor (ER) α endocrine therapy in ER+/FGFR1-amplified breast cancer Cancer Research. 75: 2435-2435. DOI: 10.1158/1538-7445.Am2015-2435 |
0.506 |
|
| 2015 |
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nature Genetics. DOI: 10.1038/ng.3391 |
0.359 |
|
| 2014 |
Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/Oncology and Stem Cell Therapy. 7: 142-8. PMID 25467032 DOI: 10.1016/J.Hemonc.2014.09.007 |
0.454 |
|
| 2014 |
Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. The Journal of Clinical Investigation. 124: 5490-502. PMID 25401474 DOI: 10.1172/Jci72573 |
0.535 |
|
| 2014 |
Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: S1-S112. PMID 25228531 DOI: 10.1158/1078-0432.Ccr-14-2123 |
0.339 |
|
| 2014 |
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research : Bcr. 16: 406. PMID 25103565 DOI: 10.1186/S13058-014-0406-X |
0.487 |
|
| 2014 |
Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Research. 74: 5184-94. PMID 25100563 DOI: 10.1158/0008-5472.Can-14-0663 |
0.342 |
|
| 2014 |
McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomedical Optics Express. 5: 2247-61. PMID 25071962 DOI: 10.1364/Boe.5.002247 |
0.431 |
|
| 2014 |
Mayer IA, Arteaga CL. PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2932-4. PMID 25071103 DOI: 10.1200/Jco.2014.55.9591 |
0.542 |
|
| 2014 |
Rexer BN, Arteaga CL. Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. Breast Cancer Research : Bcr. 16: 303. PMID 25032256 DOI: 10.1186/Bcr3635 |
0.319 |
|
| 2014 |
Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 5: 9049-64. PMID 24979294 DOI: 10.18632/Oncotarget.2022 |
0.531 |
|
| 2014 |
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, ... ... Arteaga CL, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. The Oncologist. 19: 616-22. PMID 24797823 DOI: 10.1200/Jco.2014.32.15_Suppl.11089 |
0.366 |
|
| 2014 |
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment. 145: 389-99. PMID 24722917 DOI: 10.1007/S10549-014-2945-3 |
0.365 |
|
| 2014 |
Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1202-9. PMID 24663045 DOI: 10.1200/Jco.2013.54.0518 |
0.52 |
|
| 2014 |
Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25: 282-303. PMID 24651011 DOI: 10.1016/J.Ccr.2014.02.025 |
0.417 |
|
| 2014 |
Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment. Journal of the American Heart Association. 3: e000780. PMID 24584746 DOI: 10.1161/Jaha.113.000780 |
0.36 |
|
| 2014 |
Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen A. Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy. Journal of Biomedical Optics. 19: 025001. PMID 24496495 DOI: 10.1117/1.Jbo.19.2.025001 |
0.507 |
|
| 2014 |
Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Research : Bcr. 16: R9. PMID 24451154 DOI: 10.1186/Bcr3601 |
0.518 |
|
| 2014 |
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1757-67. PMID 24398047 DOI: 10.1158/1078-0432.Ccr-13-2332 |
0.436 |
|
| 2014 |
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, ... ... Arteaga CL, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discovery. 4: 232-45. PMID 24356096 DOI: 10.1158/2159-8290.Cd-13-0286 |
0.467 |
|
| 2014 |
Mayer IA, Fasching PA, Gnant M, Campone M, Blumenstein L, Dutta A, Germa C, Li R, Arteaga CL. Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, PIK3CA mutant or wild-type, breast cancer (BC). Journal of Clinical Oncology. 32: TPS655-TPS655. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps655 |
0.414 |
|
| 2014 |
Abramson VG, Lehmann B, Mayer IA, Arteaga CL, Pietenpol JA. TBCRC028: A phase Ib/II trial of GDC-0941 (a PI3K inhibitor) in combination with cisplatin in metastatic androgen receptor-negative triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1148 |
0.428 |
|
| 2014 |
Jansen VM, Bhola NE, Bafna S, Giltnane JM, Balko JM, Dugger TC, Arteaga CL. Inhibition of polo-like kinase 1 (PLK1) in endocrine-resistant ER+ breast cancer. Journal of Clinical Oncology. 32: 515-515. DOI: 10.1200/Jco.2014.32.15_Suppl.515 |
0.514 |
|
| 2014 |
Hanker AB, Bulen B, Brewer MR, Young CD, Farrar KM, Cook RS, Stricker TP, Arteaga CL. Abstract 1822: HER2/PIK3CAH1047R transgenic tumors develop acquired resistance to triple therapy with trastuzumab, pertuzumab, and PI3K inhibitors via multiple mechanisms Cancer Research. 75: 1822-1822. DOI: 10.1158/1538-7445.Sabcs14-Pd5-8 |
0.507 |
|
| 2014 |
Garrett JT, Becker J, Estrada MV, Arteaga CL. Abstract LB-212: HER2-overexpressing breast cancer xenografts amplify FGFR signaling upon acquisition of resistance to dual blockade with trastuzumab and lapatinib Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-212 |
0.496 |
|
| 2014 |
Young CD, Zimmerman LJ, Gatza ML, Morrison MM, Whitwell CA, Bhola NE, Hanker AB, Stricker T, Patel P, Brantley-Sieders DM, Perou CM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer Cancer Research. 74: 970-970. DOI: 10.1158/1538-7445.Am2014-970 |
0.521 |
|
| 2014 |
Bhola NE, Jansen V, Arteaga C. Abstract 1945: TORC inhibitors increase the cancer stem cell (CSC) population and Notch signaling in triple negative breast cancer Cancer Research. 74: 1945-1945. DOI: 10.1158/1538-7445.Am2014-1945 |
0.514 |
|
| 2013 |
Sanders M, Kuba MG, Farley J, Lai D, Su Z, Mayer IA, Means-Powell JA, Vnenzak-Jones C, Levy MA, Pao W, Arteaga CL, Abramson VG. Clinical and pathologic characteristics of patients with PI3K-mutant breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 8. PMID 28136604 DOI: 10.1200/Jco.2013.31.26_Suppl.8 |
0.469 |
|
| 2013 |
Arteaga CL. Progress in breast cancer: overview. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6353-9. PMID 24298065 DOI: 10.1158/1078-0432.Ccr-13-2549 |
0.414 |
|
| 2013 |
Hanker AB, Cook RS, Arteaga CL. Mouse models and anti-HER2 therapies. Oncotarget. 4: 1866-7. PMID 24272818 DOI: 10.18632/Oncotarget.1481 |
0.56 |
|
| 2013 |
Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Research. 73: 6164-74. PMID 24130112 DOI: 10.1158/0008-5472.Can-13-0527 |
0.343 |
|
| 2013 |
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, et al. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. The Journal of Clinical Investigation. 123: 4329-43. PMID 23999432 DOI: 10.1172/Jci66764 |
0.557 |
|
| 2013 |
Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Research. 73: 6346-58. PMID 23966295 DOI: 10.1158/0008-5472.Can-13-1385 |
0.475 |
|
| 2013 |
Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5390-401. PMID 23948973 DOI: 10.1158/1078-0432.Ccr-13-1038 |
0.446 |
|
| 2013 |
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/Pnas.1303204110 |
0.554 |
|
| 2013 |
Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, ... ... Arteaga CL, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Research. 73: 6024-35. PMID 23928993 DOI: 10.1158/0008-5472.Can-13-1198 |
0.505 |
|
| 2013 |
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Research. 73: 6013-23. PMID 23918797 DOI: 10.1158/0008-5472.Can-13-1191 |
0.512 |
|
| 2013 |
Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Research : Bcr. 15: 209. PMID 23905624 DOI: 10.1186/Bcr3435 |
0.38 |
|
| 2013 |
Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CL. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Research : Bcr. 15: R55. PMID 23844554 DOI: 10.1186/Bcr3449 |
0.499 |
|
| 2013 |
Ciruelos E, Cortes-Funes H, Ghanem I, Manso L, Arteaga C. Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. Anti-Cancer Drugs. 24: 769-780. PMID 23838677 DOI: 10.1097/Cad.0B013E328363Adc5 |
0.532 |
|
| 2013 |
Rexer BN, Arteaga CL. Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications. Cancer Research. 73: 3817-20. PMID 23794708 DOI: 10.1158/0008-5472.Can-13-0687 |
0.489 |
|
| 2013 |
Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3703-13. PMID 23697991 DOI: 10.1158/1078-0432.Ccr-13-0623 |
0.414 |
|
| 2013 |
Rexer BN, Shyr Y, Arteaga CL. Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2073-5. PMID 23650407 DOI: 10.1200/Jco.2012.48.5243 |
0.553 |
|
| 2013 |
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research. 73: 4075-85. PMID 23633485 DOI: 10.1158/0008-5472.Can-12-4579 |
0.514 |
|
| 2013 |
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. The Journal of Clinical Investigation. 123: 1348-58. PMID 23391723 DOI: 10.1172/Jci65416 |
0.472 |
|
| 2013 |
Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 610-9. PMID 23224399 DOI: 10.1158/1078-0432.Ccr-12-2024 |
0.539 |
|
| 2013 |
Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200. PMID 23204226 DOI: 10.1158/0008-5472.Can-12-2440 |
0.5 |
|
| 2013 |
Iwata H, Baselga J, Campone M, Arteaga CL, Cortes J, Jonat W, De Laurentiis M, Ciruelos E, Janni W, Bachelot T, Lonning PE, Ma C, O'Regan R, Di Tomaso E, Bharani-Dharan B, et al. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. Journal of Clinical Oncology. 31: TPS650-TPS650. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps650 |
0.406 |
|
| 2013 |
Dillon LM, Bean JR, Yang W, Balko JM, McDonald WH, Friedman DB, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. Abstract PR05: P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Pr05 |
0.522 |
|
| 2013 |
Arteaga CL. Abstract IA22: Rationale and current status of development of PI3K/TOR pathway inhibitors Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Ia22 |
0.503 |
|
| 2013 |
Young CD, Zimmerman LJ, Whitwell CA, Hanker AB, Stricker T, Brantley-Sieders DM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B015 |
0.506 |
|
| 2013 |
Morrison MM, Stanford J, Young C, Vaught D, Williams A, williams m, Perou CM, Arteaga CL, Cook RS. Abstract A053: ErbB3 downregulation enhances luminal breast tumor response to antiestrogens Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A053 |
0.551 |
|
| 2013 |
Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, Sanchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A007 |
0.541 |
|
| 2013 |
Dillon LM, Bean JR, Balko JM, McDonald WH, Friedman DB, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TW. Abstract LB-37: P-REX1 is a novel PTEN-interacting protein that activates PI3K signaling in breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-37 |
0.476 |
|
| 2013 |
Garrett JT, Sutton CR, Bialucha CU, Ettenberg SA, Wallweber J, DeFazio-Eli L, Arteaga CL. Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors . Cancer Research. 73: 5461-5461. DOI: 10.1158/1538-7445.Am2013-5461 |
0.446 |
|
| 2013 |
Fox EM, Balko JM, Arteaga CL. Abstract 3563: Deep kinome sequencing identifies a novel D189Y mutation in the Src family kinase LYN as a possible mediator of antiestrogen resistance in ER+ breast cancer . Endocrinology. DOI: 10.1158/1538-7445.Am2013-3563 |
0.445 |
|
| 2012 |
Doimi FF, Balko JM, Arteaga CL, Gómez HL. Ki-67 expression in residual triple-negative breast tumors after neoadjuvant chemotherapy to predict for recurrence-free survival. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 89. PMID 28142498 DOI: 10.1200/Jco.2012.30.30_Suppl.89 |
0.456 |
|
| 2012 |
Miller TW, Blum DL, Pareh D, Yan H, Sutton CR, Dugger TC, Salazar LG, Wu W, Reyzer ML, Disis ML, Mernaugh R, Arteaga CL. Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 77. PMID 28142426 DOI: 10.1200/Jco.2012.30.30_Suppl.77 |
0.42 |
|
| 2012 |
Fox EM, Arteaga CL, Miller TW. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer. Frontiers in Oncology. 2: 145. PMID 23087906 DOI: 10.3389/Fonc.2012.00145 |
0.498 |
|
| 2012 |
Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5816-28. PMID 22932669 DOI: 10.1158/1078-0432.CCR-12-1141 |
0.492 |
|
| 2012 |
Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL. Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. Molecular Cancer Therapeutics. 11: 2301-5. PMID 22879364 DOI: 10.1158/1535-7163.Mct-12-0511 |
0.525 |
|
| 2012 |
Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, ... ... Arteaga CL, et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine. 18: 1052-9. PMID 22683778 DOI: 10.1038/Nm.2795 |
0.52 |
|
| 2012 |
Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Research. 72: 3228-37. PMID 22552284 DOI: 10.1158/0008-5472.Can-11-3747 |
0.447 |
|
| 2012 |
Sprung RW, Martinez MA, Carpenter KL, Ham AJ, Washington MK, Arteaga CL, Sanders ME, Liebler DC. Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue. Journal of Proteome Research. 11: 3498-505. PMID 22530795 DOI: 10.1021/Pr300130T |
0.3 |
|
| 2012 |
Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Critical Reviews in Oncogenesis. 17: 1-16. PMID 22471661 DOI: 10.1615/Critrevoncog.V17.I1.20 |
0.53 |
|
| 2012 |
Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Research. 72: 2672-82. PMID 22461506 DOI: 10.1158/0008-5472.Can-11-3594 |
0.538 |
|
| 2012 |
Balko JM, Arteaga CL. Molecular signatures of lung cancer: defining new diagnostic and therapeutic paradigms. Molecular Diagnosis & Therapy. 16: 1-6. PMID 22339590 DOI: 10.1007/Bf03256423 |
0.328 |
|
| 2012 |
Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 612-8. PMID 22298893 DOI: 10.1158/1078-0432.Ccr-11-2019 |
0.367 |
|
| 2012 |
Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomedical Optics Express. 3: 75-85. PMID 22254170 DOI: 10.1364/Boe.3.000075 |
0.507 |
|
| 2012 |
Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America. 109: 221-6. PMID 22178756 DOI: 10.1073/Pnas.1115802109 |
0.459 |
|
| 2012 |
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews. Clinical Oncology. 9: 16-32. PMID 22124364 DOI: 10.1038/Nrclinonc.2011.177 |
0.493 |
|
| 2012 |
Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors Proceedings of the National Academy of Sciences of the United States of America. 109: 2718-2723. PMID 21368164 DOI: 10.1073/Pnas.1018001108 |
0.503 |
|
| 2012 |
Mayer IA, Abramson VG, Balko JM, Isakoff SJ, Kuba MG, Sanders M, Forero-Torres A, Yap JT, Abbeele ADVD, Li Y, Arteaga CL, Winer EP, Cancers SUtCPKiW. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). Journal of Clinical Oncology. 30: 510-510. DOI: 10.1200/Jco.2012.30.15_Suppl.510 |
0.416 |
|
| 2012 |
Balko JM, Sanders M, Kuba MG, Pinto JA, Doimi FF, Gomez HL, Arteaga CL. A gene expression signature of MEK pathway activation to predict survival in triple-negative breast cancer. Journal of Clinical Oncology. 30: 1024-1024. DOI: 10.1200/Jco.2012.30.15_Suppl.1024 |
0.448 |
|
| 2012 |
Young CD, Kuba MG, Owens P, Balko JM, Pfefferle A, Sanchez V, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Abstract LB-103: Conditional loss of ErbB3 delays mammary gland hyperplasias induced by mutant PIK3CA in transgenic mice, but does not affect mammary tumor latency, gene expression or signaling Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-103 |
0.498 |
|
| 2012 |
Hanker AB, Kuba MG, Sanchez V, Sutton CR, Pfefferle A, Balko JM, Perou CM, Cook RS, Arteaga CL. Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo Cancer Research. 72: 4875-4875. DOI: 10.1158/1538-7445.Am2012-4875 |
0.318 |
|
| 2012 |
Fox EM, Davies BR, Arteaga CL. Abstract 4825: Inhibition of AKT abrogates resistance to endocrine therapy in estrogen receptor positive breast cancer Cancer Research. 72: 4825-4825. DOI: 10.1158/1538-7445.Am2012-4825 |
0.533 |
|
| 2012 |
Garrett JT, Sutton CR, Cook RS, Arteaga CL. Abstract 3867: Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function completely: Clinical implications Cancer Research. 72: 3867-3867. DOI: 10.1158/1538-7445.Am2012-3867 |
0.492 |
|
| 2012 |
Bhola NE, Balko J, Arteaga C. Abstract 3475: Inhibition of the TGFβ pathway inhibits chemotherapy-induced enrichment of breast cancer stem cells in triple-negative breast cancer Cancer Research. 72: 3475-3475. DOI: 10.1158/1538-7445.Am2012-3475 |
0.545 |
|
| 2012 |
Ghosh R, Narasanna A, Chakrabarty A, Engelman JA, Arteaga CL. Abstract 3: HER2 gene-amplified human breast cancer cells harboring a gatekeeper T768M mutation in HER2 overexpress EGFR ligands and are sensitive to dual therapeutic blockade of EGFR and HER2 Cancer Research. 72: 3-3. DOI: 10.1158/1538-7445.Am2012-3 |
0.505 |
|
| 2012 |
Liu S, Meng X, Liu W, Miller T, Lu Y, Zhang F, Arteaga CL, Mills GB, Gonzalez-Angulo AM. Abstract 2702: Effects of Src and IGF1R inhibition on acquired endocrine therapy resistant breast cancer Cancer Research. 72: 2702-2702. DOI: 10.1158/1538-7445.Am2012-2702 |
0.441 |
|
| 2012 |
Fox EM, Balko JM, Arteaga CL. Abstract PD01-04: Deep kinome sequencing identifies a novel D189Y mutation in the Src family kinase LYN as a possible mediator of antiestrogen resistance in ER+ breast cancer Cancer Research. 72: 3563-3563. DOI: 10.1158/0008-5472.Sabcs12-Pd01-04 |
0.55 |
|
| 2012 |
Saura C, Burris H, Arteaga C, Mayer I, Germa C, Fretault N, Sternberg D, Trandafir L, Massacesi C, Rodon J. 193 Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC) European Journal of Cancer. 48: S96. DOI: 10.1016/S0959-8049(12)70261-7 |
0.426 |
|
| 2011 |
Balko JM, Cook RS, Miller TW, Bhola NE, Sanders M, Granja-Ingram NM, Sanchez V, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Arteaga CL. Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10509. PMID 28022377 DOI: 10.1200/Jco.2011.29.15_Suppl.10509 |
0.489 |
|
| 2011 |
Krop IE, Flores L, Najita JS, Mayer IA, Hobday TJ, Falkson CI, Arteaga CL, Wolff AC, Dees EC, Rimawi MF, Nanda R, Josephs K, Lin NU, Winer EP. The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 528. PMID 28021333 DOI: 10.1200/Jco.2011.29.15_Suppl.528 |
0.423 |
|
| 2011 |
Garrett JT, Chakrabarty A, Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2: 1314-1319. PMID 22248929 DOI: 10.18632/Oncotarget.409 |
0.445 |
|
| 2011 |
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, ... ... Arteaga CL, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 1: 352-65. PMID 22145099 DOI: 10.1158/2159-8290.Cd-11-0106 |
0.451 |
|
| 2011 |
Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Research : Bcr. 13: 224. PMID 22114931 DOI: 10.1186/Bcr3039 |
0.544 |
|
| 2011 |
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Adam Smith R, Maira SM, Charles Manning H, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, ... ... Arteaga CL, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer Cancer Discovery. 1: 338-351. PMID 22049316 DOI: 10.1158/2159-8290.Cd-11-0101 |
0.514 |
|
| 2011 |
Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4452-61. PMID 22010023 DOI: 10.1200/Jco.2010.34.4879 |
0.551 |
|
| 2011 |
Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Research. 71: 6773-84. PMID 21908557 DOI: 10.1158/0008-5472.Can-11-1295 |
0.501 |
|
| 2011 |
Yang X, Turke AB, Qi J, Song Y, Rexer BN, Miller TW, Jänne PA, Arteaga CL, Cantley LC, Engelman JA, Asara JM. Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Research. 71: 5965-75. PMID 21775521 DOI: 10.1158/0008-5472.Can-11-0445 |
0.456 |
|
| 2011 |
Glück S, Arteaga CL, Osborne CK. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5559-61. PMID 21764887 DOI: 10.1158/1078-0432.Ccr-10-2051 |
0.494 |
|
| 2011 |
Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4919-21. PMID 21670086 DOI: 10.1158/1078-0432.Ccr-11-1218 |
0.495 |
|
| 2011 |
Chow A, Arteaga CL, Wang SE. When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene. Journal of Mammary Gland Biology and Neoplasia. 16: 81-8. PMID 21590373 DOI: 10.1007/S10911-011-9206-4 |
0.551 |
|
| 2011 |
Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 30: 4163-74. PMID 21499296 DOI: 10.1038/Onc.2011.130 |
0.491 |
|
| 2011 |
Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis Cancer Research. 71: 3941-3951. PMID 21482676 DOI: 10.1158/0008-5472.Can-10-3775 |
0.485 |
|
| 2011 |
Arteaga CL. ERBB receptors in cancer: signaling from the inside. Breast Cancer Research : Bcr. 13: 304. PMID 21457523 DOI: 10.1186/Bcr2829 |
0.411 |
|
| 2011 |
Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America. 108: 5021-6. PMID 21385943 DOI: 10.1073/Pnas.1016140108 |
0.478 |
|
| 2011 |
Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance Clinical Cancer Research. 17: 2024-2034. PMID 21346144 DOI: 10.1158/1078-0432.Ccr-10-2567 |
0.495 |
|
| 2011 |
Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, ... ... Arteaga CL, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 71: 1871-82. PMID 21324925 DOI: 10.1158/0008-5472.Can-10-1872 |
0.536 |
|
| 2011 |
Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biology & Therapy. 11: 793-800. PMID 21307659 DOI: 10.4161/Cbt.11.9.15045 |
0.474 |
|
| 2011 |
Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 952-8. PMID 21248299 DOI: 10.1158/1078-0432.Ccr-09-1947 |
0.464 |
|
| 2011 |
Yan L, Rosen N, Arteaga C. Targeted cancer therapies Chinese Journal of Cancer. 30: 1-4. PMID 21192839 DOI: 10.5732/Cjc.010.10553 |
0.52 |
|
| 2011 |
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 166-73. PMID 21135276 DOI: 10.1200/Jco.2009.27.7814 |
0.504 |
|
| 2011 |
Balko JM, Arteaga CL. Dead-box or black-box: is DDX1 a potential biomarker in breast cancer? Breast Cancer Research and Treatment. 127: 65-7. PMID 20694745 DOI: 10.1007/S10549-010-1105-7 |
0.421 |
|
| 2011 |
Arteaga C. The phosphatidylinositol-3 kinase/mTOR pathway: new agents Breast Cancer Research. 13: 1-9. DOI: 10.1186/Bcr3007 |
0.459 |
|
| 2011 |
Garrett J, Rinehart C, Chakrabarty A, Dave B, Pao W, Manning C, Chang J, Arteaga C. Abstract 231: Upregulation of HER3 (ErbB3) levels and function counteracts the antitumor effect of HER2 and PI3K inhibitors Cancer Research. 71: 231-231. DOI: 10.1158/1538-7445.Am2011-231 |
0.502 |
|
| 2011 |
Arteaga CL. Abstract CN03-01: Mechanistic basis for treatment combinations with PI3K inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-Cn03-01 |
0.497 |
|
| 2011 |
Bhola N, Arteaga C. PD08-04: Inhibition of the TGFb/TGFbR2 Pathway Prevents Enrichment of Drug-Resistant Breast Cancer Stem Cells by Anti-Cancer Chemotherapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd08-04 |
0.54 |
|
| 2011 |
Sanders M, Sprung R, Ham A, Sanchez V, Manning S, Arteaga C, Liebler D. P1-07-19: Analysis of HER2−Status in Breast Cancer by Mass Spectrometry in Archival, Formalin-Fixed Tissues. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-07-19 |
0.388 |
|
| 2011 |
Miller T, Arteaga C. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer Breast Diseases: a Year Book Quarterly. 22: 367-370. DOI: 10.1016/J.BREASTDIS.2011.10.024 |
0.348 |
|
| 2010 |
Rejniak KA, Wang SE, Bryce NS, Chang H, Parvin B, Jourquin J, Estrada L, Gray JW, Arteaga CL, Weaver AM, Quaranta V, Anderson AR. Linking changes in epithelial morphogenesis to cancer mutations using computational modeling. Plos Computational Biology. 6. PMID 20865159 DOI: 10.1371/Journal.Pcbi.1000900 |
0.354 |
|
| 2010 |
Arteaga CL. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Current Topics in Microbiology and Immunology. 347: 189-208. PMID 20593313 DOI: 10.1007/82_2010_54 |
0.421 |
|
| 2010 |
Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 Oncogene. 29: 5193-5203. PMID 20581867 DOI: 10.1038/Onc.2010.257 |
0.504 |
|
| 2010 |
Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Research : Bcr. 12: R41. PMID 20576088 DOI: 10.1186/Bcr2595 |
0.501 |
|
| 2010 |
Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. The Journal of Clinical Investigation. 120: 2406-13. PMID 20530877 DOI: 10.1172/Jci41680 |
0.557 |
|
| 2010 |
Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 29: 3335-48. PMID 20383197 DOI: 10.1038/Onc.2010.112 |
0.51 |
|
| 2010 |
Mayer IA, Arteaga CL. Does lapatinib work against HER2-negative breast cancers? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1355-7. PMID 20179241 DOI: 10.1158/1078-0432.Ccr-09-3223 |
0.488 |
|
| 2010 |
Mayer IA, Meszoely IM, Sanders M, Shyr Y, Abramson VG, Means-Powell JA, Chakravarthy AB, Arteaga CL, Pietenpol JA. A phase II neoadjuvant study of cisplatin/paclitaxel with or without RAD001 in patients with triple-negative (TN) locally advanced breast cancer (BC). Journal of Clinical Oncology. 28: TPS119-TPS119. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps119 |
0.398 |
|
| 2010 |
Hanker AB, Chakrabarty A, Arteaga CL. Abstract B39: Identification of kinases that compensate for PI3K inhibition in breast cancer cells Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B39 |
0.476 |
|
| 2010 |
Bi X, Rexer B, Arteaga CL, Guo M, Li M, Mahadevan-Jansen A. Determination of HER2 amplification status in breast cancer cells using Raman spectroscopy Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7560. DOI: 10.1117/12.858804 |
0.472 |
|
| 2009 |
Wang SE, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. A mathematical model quantifies proliferation and motility effects of TGF-β on cancer cells. Computational and Mathematical Methods in Medicine. 10: 71-83. PMID 26000030 DOI: 10.1080/17486700802171993 |
0.331 |
|
| 2009 |
Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Research. 70: 299-308. PMID 20028874 DOI: 10.1158/0008-5472.Can-09-1845 |
0.498 |
|
| 2009 |
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7266-76. PMID 19934303 DOI: 10.1158/1078-0432.Ccr-09-1665 |
0.521 |
|
| 2009 |
Anderson AR, Hassanein M, Branch KM, Lu J, Lobdell NA, Maier J, Basanta D, Weidow B, Narasanna A, Arteaga CL, Reynolds AB, Quaranta V, Estrada L, Weaver AM. Microenvironmental independence associated with tumor progression. Cancer Research. 69: 8797-806. PMID 19887618 DOI: 10.1158/0008-5472.Can-09-0437 |
0.363 |
|
| 2009 |
Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4712-21. PMID 19584166 DOI: 10.1158/1078-0432.Ccr-08-2635 |
0.382 |
|
| 2009 |
Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4518-20. PMID 19584146 DOI: 10.1158/1078-0432.Ccr-09-0872 |
0.485 |
|
| 2009 |
Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, Arteaga CL, Segall JE. ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3733-9. PMID 19458057 DOI: 10.1158/1078-0432.Ccr-08-2163 |
0.486 |
|
| 2009 |
Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Research. 69: 4192-201. PMID 19435893 DOI: 10.1158/0008-5472.Can-09-0042 |
0.513 |
|
| 2009 |
Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Research. 69: 475-82. PMID 19147560 DOI: 10.1158/0008-5472.Can-08-2649 |
0.473 |
|
| 2009 |
Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nature Chemical Biology. 5: 108-17. PMID 19136975 DOI: 10.1038/Nchembio.140 |
0.411 |
|
| 2009 |
Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 11: 204-12. PMID 19130143 DOI: 10.1007/S11307-008-0193-9 |
0.325 |
|
| 2009 |
Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists Cell Cycle. 8: 18-22. PMID 19106609 DOI: 10.4161/Cc.8.1.7324 |
0.436 |
|
| 2009 |
Rexer B, Chakrabarthy A, Rinehart C, Hill S, Olivares M, Ham A, Liebler DC, Arteaga CL. Abstract PR-6: Src family kinases mediate PI3K‐Akt pathway activation and resistance to lapatinib in HER2‐overexpressing human breast cancer cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Pr-6 |
0.46 |
|
| 2009 |
Migliaccio I, Gutierrez M, Wu M, Wong H, Pavlick A, Hilsenbeck S, Horlings H, Rimawi M, Berns K, Bernards R, Osborne C, Arteaga C, Chang J. PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). Cancer Research. 69: 34. DOI: 10.1158/0008-5472.Sabcs-34 |
0.482 |
|
| 2008 |
Guix M, Mayer IA, Meszoely IM, Arteaga CL. Evaluation of biological agents targeted at early-stage disease. Breast Cancer Research : Bcr. S25. PMID 19128439 DOI: 10.1186/Bcr2185 |
0.511 |
|
| 2008 |
Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Research. 68: 9141-6. PMID 19010885 DOI: 10.1158/0008-5472.Can-08-1127 |
0.492 |
|
| 2008 |
Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, Sledge GW, Davidson NE. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6277-83. PMID 18829509 DOI: 10.1158/1078-0432.Ccr-08-0482 |
0.505 |
|
| 2008 |
Miller TW, Shin I, Kagawa N, Evans DB, Waterman MR, Arteaga CL. Aromatase is phosphorylated in situ at serine-118. The Journal of Steroid Biochemistry and Molecular Biology. 112: 95-101. PMID 18822378 DOI: 10.1016/J.Jsbmb.2008.09.001 |
0.336 |
|
| 2008 |
Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Research. 68: 7304-12. PMID 18794117 DOI: 10.1158/0008-5472.Can-07-6777 |
0.746 |
|
| 2008 |
Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Molecular and Cellular Biology. 28: 5605-20. PMID 18625725 DOI: 10.1128/Mcb.00787-08 |
0.518 |
|
| 2008 |
Belkhiri A, Dar AA, Fa Peng D, Razvi MH, Rinehart C, Arteaga CL, El-Rifai W. Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells Clinical Cancer Research. 14: 4564-4571. PMID 18579663 DOI: 10.1158/1078-0432.Ccr-08-0121 |
0.411 |
|
| 2008 |
Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of Clinical Investigation. 118: 2609-19. PMID 18568074 DOI: 10.1172/Jci34588 |
0.468 |
|
| 2008 |
Sanders ME, Dias EC, Xu BJ, Mobley JA, Billheimer D, Roder H, Grigorieva J, Dowsett M, Arteaga CL, Caprioli RM. Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. Journal of Proteome Research. 7: 1500-7. PMID 18386930 DOI: 10.1021/Pr7008109 |
0.379 |
|
| 2008 |
Keedy VL, Arteaga CL, Johnson DH. Does gefitinib shorten lung cancer survival? Chaos redux. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2428-30. PMID 18378565 DOI: 10.1200/Jco.2008.16.0374 |
0.4 |
|
| 2008 |
Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, et al. TGF-β signalling-related markers in cancer patients with bone metastasis Biomarkers. 13: 217-236. PMID 18270872 DOI: 10.1080/13547500701676019 |
0.365 |
|
| 2008 |
Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel Cancer Research. 68: 589-596. PMID 18199556 DOI: 10.1158/0008-5472.Can-07-1570 |
0.409 |
|
| 2008 |
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, ... ... Arteaga CL, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 897-906. PMID 18180460 DOI: 10.1200/Jco.2007.13.5939 |
0.547 |
|
| 2008 |
Yang S, Park K, Turkson J, Arteaga CL. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. Experimental Cell Research. 314: 413-9. PMID 17927978 DOI: 10.1016/J.Yexcr.2007.09.002 |
0.391 |
|
| 2008 |
Calvo-Aller E, Baselga J, Glatt S, Cleverly A, Lahn M, Arteaga CL, Rothenberg ML, Carducci MA. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase Journal of Clinical Oncology. 26: 14554-14554. DOI: 10.1200/Jco.2008.26.15_Suppl.14554 |
0.392 |
|
| 2007 |
Criswell TL, Arteaga CL. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. The Journal of Biological Chemistry. 282: 32491-500. PMID 17823118 DOI: 10.1074/Jbc.M704434200 |
0.43 |
|
| 2007 |
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clinical Cancer Research. 13: 4909-4919. PMID 17699871 DOI: 10.1158/1078-0432.Ccr-07-0701 |
0.508 |
|
| 2007 |
Yang L, Amann JM, Kikuchi T, Porta R, Guix M, Gonzalez A, Park KH, Billheimer D, Arteaga CL, Tai HH, DuBois R, Carbone DP, Johnson DH. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Research. 67: 5587-93. PMID 17575121 DOI: 10.1158/0008-5472.Can-06-2287 |
0.424 |
|
| 2007 |
Arteaga CL. HER3 and mutant EGFR meet MET. Nature Medicine. 13: 675-7. PMID 17554333 DOI: 10.1038/Nm0607-675 |
0.445 |
|
| 2007 |
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biology & Therapy. 6: 561-70. PMID 17495520 DOI: 10.4161/Cbt.6.4.3851 |
0.482 |
|
| 2007 |
Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. The Journal of Clinical Investigation. 117: 1305-13. PMID 17415413 DOI: 10.1172/Jci30740 |
0.419 |
|
| 2007 |
Hinow P, Wang SE, Arteaga CL, Webb GF. relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. Theoretical Biology & Medical Modelling. 4: 14. PMID 17407594 DOI: 10.1186/1742-4682-4-14 |
0.49 |
|
| 2007 |
Arteaga CL. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1071-3. PMID 17317812 DOI: 10.1158/1078-0432.Ccr-06-2717 |
0.509 |
|
| 2007 |
Wang SE, Narasanna A, Whitell CW, Wu FY, Friedman DB, Arteaga CL. Convergence of p53 and transforming growth factor beta (TGFbeta) signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells. The Journal of Biological Chemistry. 282: 5661-9. PMID 17204482 DOI: 10.1074/Jbc.M608499200 |
0.44 |
|
| 2007 |
Friedman DB, Wang SE, Whitwell CW, Caprioli RM, Arteaga CL. Multivariable difference gel electrophoresis and mass spectrometry: a case study on transforming growth factor-beta and ERBB2 signaling. Molecular & Cellular Proteomics : McP. 6: 150-69. PMID 17028091 DOI: 10.1074/Mcp.D600001-Mcp200 |
0.374 |
|
| 2007 |
Dua R, Nhonthachit P, Rinehart C, Arteaga CL, Nahta R, Esteva FJ, Winslow J, Bates M, Petropoulos C. Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines Journal of Clinical Oncology. 25: 2533-2533. DOI: 10.1200/Jco.2007.25.18_Suppl.2533 |
0.457 |
|
| 2007 |
Moulder SL, O’Neill A, Arteaga C, Pins M, Sparano J, Sledge G, Davidson N. Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC) Journal of Clinical Oncology. 25: 1033-1033. DOI: 10.1200/Jco.2007.25.18_Suppl.1033 |
0.396 |
|
| 2006 |
Shin I, Arteaga CL. Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells Iubmb Life. 58: 664-669. PMID 17085387 DOI: 10.1080/15216540601001681 |
0.431 |
|
| 2006 |
Perez-Torres M, Guix M, Gonzalez A, Arteaga CL. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. The Journal of Biological Chemistry. 281: 40183-92. PMID 17082181 DOI: 10.1074/Jbc.M607958200 |
0.45 |
|
| 2006 |
Wang SE, Shin I, Wu FY, Friedman DB, Arteaga CL. HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. Cancer Research. 66: 9591-600. PMID 17018616 DOI: 10.1158/0008-5472.Can-06-2071 |
0.416 |
|
| 2006 |
Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis (New York, N.Y. : 2000). 44: 477-86. PMID 16991114 DOI: 10.1002/Dvg.20243 |
0.303 |
|
| 2006 |
Biswas S, Criswell TL, Wang SE, Arteaga CL. Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4142-6. PMID 16857784 DOI: 10.1158/1078-0432.Ccr-06-0952 |
0.467 |
|
| 2006 |
Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, Arteaga CL. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Research. 66: 6990-7. PMID 16849543 DOI: 10.1158/0008-5472.Can-06-1042 |
0.405 |
|
| 2006 |
Cornett DS, Mobley JA, Dias EC, Andersson M, Arteaga CL, Sanders ME, Caprioli RM. A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Molecular & Cellular Proteomics : McP. 5: 1975-83. PMID 16849436 DOI: 10.1074/Mcp.M600119-Mcp200 |
0.336 |
|
| 2006 |
Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3722-5. PMID 16847283 DOI: 10.1200/Jco.2006.06.5268 |
0.556 |
|
| 2006 |
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell. 10: 25-38. PMID 16843263 DOI: 10.1016/J.Ccr.2006.05.023 |
0.445 |
|
| 2006 |
Arteaga CL. EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Cancer Cell. 9: 421-3. PMID 16766261 DOI: 10.1016/J.Ccr.2006.05.014 |
0.387 |
|
| 2006 |
Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, Baselga J, Arteaga CL. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Research. 66: 2162-72. PMID 16489017 DOI: 10.1158/0008-5472.Can-05-3304 |
0.401 |
|
| 2006 |
Shin I, Miller T, Arteaga CL. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1008s-1012s. PMID 16467117 DOI: 10.1158/1078-0432.Ccr-05-2352 |
0.403 |
|
| 2006 |
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 997s-1000s. PMID 16467115 DOI: 10.1158/1078-0432.Ccr-05-2268 |
0.401 |
|
| 2006 |
Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFβ receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression Oncogene. 25: 3408-3423. PMID 16186809 DOI: 10.1038/Sj.Onc.1208964 |
0.462 |
|
| 2005 |
Guix M, Kelley MS, Reyzer ML, Zhang J, Shyr Y, McLaren BK, Newsome-Johnson K, Lipscomb W, Dugger TC, Arteaga CL. Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774) reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: A strategy for patient selection into phase II trials with signaling inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3008. PMID 27945725 DOI: 10.1200/Jco.2005.23.16_Suppl.3008 |
0.539 |
|
| 2005 |
Arteaga CL. Inhibition of TGFbeta signaling in cancer therapy. Current Opinion in Genetics & Development. 16: 30-7. PMID 16377175 DOI: 10.1016/J.Gde.2005.12.009 |
0.44 |
|
| 2005 |
Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function. Molecular and Cellular Biology. 25: 4703-15. PMID 15899872 DOI: 10.1128/Mcb.25.11.4703-4715.2005 |
0.413 |
|
| 2005 |
Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 24: 5053-68. PMID 15856015 DOI: 10.1038/Sj.Onc.1208685 |
0.432 |
|
| 2005 |
Shin I, Edl J, Biswas S, Lin PC, Mernaugh R, Arteaga CL. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Research. 65: 2815-24. PMID 15805282 DOI: 10.1158/0008-5472.Can-04-2898 |
0.4 |
|
| 2005 |
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2445-59. PMID 15753456 DOI: 10.1200/Jco.2005.11.890 |
0.428 |
|
| 2005 |
Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 937s-43s. PMID 15701890 |
0.749 |
|
| 2005 |
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 861s-4s. PMID 15701878 |
0.34 |
|
| 2005 |
Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. The Journal of Biological Chemistry. 280: 10870-6. PMID 15657037 DOI: 10.1074/Jbc.M413223200 |
0.383 |
|
| 2005 |
Bakin AV, Stourman NV, Sekhar KR, Rinehart C, Yan X, Meredith MJ, Arteaga CL, Freeman ML. Smad3-ATF3 signaling mediates TGF-beta suppression of genes encoding Phase II detoxifying proteins. Free Radical Biology & Medicine. 38: 375-87. PMID 15629866 DOI: 10.1016/J.Freeradbiomed.2004.10.033 |
0.329 |
|
| 2004 |
Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM. Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics Cancer Research. 64: 9093-9100. PMID 15604278 DOI: 10.1158/0008-5472.Can-04-2231 |
0.383 |
|
| 2004 |
Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Research. 64: 9002-11. PMID 15604265 DOI: 10.1158/0008-5472.Can-04-2111 |
0.404 |
|
| 2004 |
Ritter CA, Bianco R, Dugger T, Forbes J, Qu S, Rinehart C, King W, Arteaga CL. Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model International Journal of Clinical Pharmacology and Therapeutics. 42: 642-643. PMID 15598031 DOI: 10.5414/CPP42642 |
0.327 |
|
| 2004 |
Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell. 5: 525-31. PMID 15193255 DOI: 10.1016/J.Ccr.2004.05.028 |
0.454 |
|
| 2004 |
Arteaga CL. Selecting the right patient for tumor therapy. Nature Medicine. 10: 577-8. PMID 15170197 DOI: 10.1038/Nm0604-577 |
0.409 |
|
| 2004 |
Arteaga CL, Truica CI. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Seminars in Oncology. 31: 3-8. PMID 15052538 DOI: 10.1053/J.Seminoncol.2004.01.006 |
0.533 |
|
| 2004 |
Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. The Journal of Biological Chemistry. 279: 24505-13. PMID 15044465 DOI: 10.1074/Jbc.M400081200 |
0.722 |
|
| 2004 |
Roberts RB, Arteaga CL, Threadgill DW. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell. 5: 115-20. PMID 14998487 DOI: 10.1016/S1535-6108(04)00032-7 |
0.335 |
|
| 2004 |
Brown KA, Roberts RL, Arteaga CL, Law BK. Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein. Breast Cancer Research : Bcr. 6: R130-9. PMID 14979923 DOI: 10.1186/Bcr762 |
0.408 |
|
| 2004 |
Arteaga CL. Cdk inhibitor p27Kip1 and hormone dependence in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 368S-71S. PMID 14734493 DOI: 10.1158/1078-0432.Ccr-031204 |
0.477 |
|
| 2004 |
Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 327S-330S. PMID 14734487 DOI: 10.1158/1078-0432.Ccr-031213 |
0.433 |
|
| 2004 |
Arteaga CL. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 289s-291s. PMID 14645415 DOI: 10.1200/Jco.2003.10.523 |
0.415 |
|
| 2004 |
Arteaga CL. Inhibiting tyrosine kinases: successes and limitations. Cancer Biology & Therapy. 2: S79-83. PMID 14508084 |
0.376 |
|
| 2004 |
YAMAOKA T, OHMORI T, INOUE F, KADOFUKU T, ANDO K, ISHIDA H, HOSAKA T, SHIRAI T, MATSUDA M, NODA M, HIROSE T, HORICHI N, NISHIO K, SAIJO N, ARTEAGA CL, et al. Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines The Showa University Journal of Medical Sciences. 16: 147-159. DOI: 10.15369/Sujms1989.16.147 |
0.405 |
|
| 2004 |
Arteaga CL. The cell game:
Sam Waksal’s fast money and false promises – and the fate of ImClone’s cancer drug Journal of Clinical Investigation. 114: 743-743. DOI: 10.1172/Jci22931 |
0.403 |
|
| 2003 |
Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Molecular and Cellular Biology. 23: 8691-703. PMID 14612410 DOI: 10.1128/Mcb.23.23.8691-8703.2003 |
0.402 |
|
| 2003 |
Moulder SL, Arteaga CL. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clinical Breast Cancer. 4: 142-5. PMID 12864943 DOI: 10.3816/Cbc.2003.N.020 |
0.453 |
|
| 2003 |
Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 3: 531-6. PMID 12842082 DOI: 10.1016/S1535-6108(03)00135-1 |
0.697 |
|
| 2003 |
Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Seminars in Oncology. 30: 3-14. PMID 12840796 |
0.345 |
|
| 2003 |
Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. The Laryngoscope. 113: 936-9. PMID 12782800 DOI: 10.1097/00005537-200306000-00004 |
0.372 |
|
| 2003 |
Johnson DH, Arteaga CL. Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2227-9. PMID 12748243 DOI: 10.1200/Jco.2003.04.001 |
0.333 |
|
| 2003 |
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22: 2812-22. PMID 12743604 DOI: 10.1038/Sj.Onc.1206388 |
0.433 |
|
| 2003 |
Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Experimental Cell Research. 284: 122-30. PMID 12648471 DOI: 10.1016/S0014-4827(02)00104-0 |
0.402 |
|
| 2003 |
Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors Seminars in Oncology. 30: 3-11. PMID 12644979 DOI: 10.1053/Sonc.2003.50027 |
0.469 |
|
| 2003 |
Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Research : Bcr. 5: 96-100. PMID 12631388 DOI: 10.1186/Bcr574 |
0.511 |
|
| 2003 |
Kurokawa H, Arteaga CL. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms Clinical Cancer Research. 9. PMID 12538508 |
0.391 |
|
| 2003 |
Come SE, Buzdar AU, Arteaga CL, Brodie AM, Davidson NE, Dowsett M, Ingle JN, Johnston SR, Lee AV, Osborne CK, Pritchard KI, Vogel VG, Winer EP, Hart CS. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 443S-6S. PMID 12538498 |
0.338 |
|
| 2003 |
Dumont N, Arteaga CL. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochemical and Biophysical Research Communications. 301: 108-12. PMID 12535648 DOI: 10.1016/S0006-291X(02)02977-7 |
0.746 |
|
| 2003 |
Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. The Journal of Biological Chemistry. 278: 3275-85. PMID 12421823 DOI: 10.1074/Jbc.M204623200 |
0.717 |
|
| 2003 |
Arteaga CL. Inhibiting Tyrosine Kinases: Successes and Limitations Cancer Biology & Therapy. 2: 78-82. DOI: 10.4161/Cbt.206 |
0.478 |
|
| 2003 |
Arteaga C. Synergy between the erbB and transforming growth factor beta signaling networks: implications for molecular therapeutics in human neoplasia Breast Cancer Research. 5: 26-26. DOI: 10.1186/Bcr685 |
0.462 |
|
| 2003 |
ARTEAGA C. Targeting HER1/EGFR: A molecular approach to cancer therapy Seminars in Oncology. 30: 3-14. DOI: 10.1016/S0093-7754(03)70010-4 |
0.452 |
|
| 2002 |
Dumont N, Arteaga CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta. Differentiation; Research in Biological Diversity. 70: 574-82. PMID 12492498 DOI: 10.1046/J.1432-0436.2002.700910.X |
0.705 |
|
| 2002 |
Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Seminars in Oncology. 29: 3-9. PMID 12422308 DOI: 10.1053/sonc.2002.35642 |
0.319 |
|
| 2002 |
Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology. 123: 1191-204. PMID 12360481 DOI: 10.1053/Gast.2002.36023 |
0.391 |
|
| 2002 |
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nature Medicine. 8: 1145-52. PMID 12244301 DOI: 10.1038/Nm759 |
0.403 |
|
| 2002 |
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? The Oncologist. 31-9. PMID 12202786 DOI: 10.1634/Theoncologist.7-Suppl_4-31 |
0.43 |
|
| 2002 |
Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in Oncology. 29: 4-10. PMID 12138392 DOI: 10.1053/sonc.2002.34047 |
0.406 |
|
| 2002 |
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Research. 62: 4132-4141. PMID 12124352 |
0.32 |
|
| 2002 |
Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. Journal of Cell Science. 115: 3193-206. PMID 12118074 |
0.312 |
|
| 2002 |
Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of Clinical Investigation. 109: 1551-9. PMID 12070302 DOI: 10.1172/Jci15234 |
0.738 |
|
| 2002 |
Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology. 29: 15-26. PMID 11894010 DOI: 10.1053/Sonc.2002.31524 |
0.456 |
|
| 2002 |
Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Molecular and Cellular Biology. 22: 2204-19. PMID 11884607 DOI: 10.1128/Mcb.22.7.2204-2219.2002 |
0.341 |
|
| 2002 |
ARTEAGA C, MOULDER S, YAKES F. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer Seminars in Oncology. 29: 4-10. DOI: 10.1016/S0093-7754(02)70121-8 |
0.501 |
|
| 2002 |
ARTEAGA C. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia Seminars in Oncology. 29: 3-9. DOI: 10.1016/S0093-7754(02)70085-7 |
0.428 |
|
| 2001 |
Busse D, Yakes FM, Lenferink AE, Arteaga CL. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Seminars in Oncology. 28: 47-55. PMID 11706396 DOI: 10.1016/S0093-7754(01)90282-9 |
0.367 |
|
| 2001 |
Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor β enhances epithelial cell survival via Akt-dependent regulation of FKHRL1 Molecular Biology of the Cell. 12: 3328-3339. PMID 11694570 DOI: 10.1091/Mbc.12.11.3328 |
0.38 |
|
| 2001 |
Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-ZD1839 (Iressa). Current Opinion in Oncology. 13: 491-8. PMID 11673690 DOI: 10.1097/00001622-200111000-00012 |
0.436 |
|
| 2001 |
Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. The Journal of Cell Biology. 153: 917-32. PMID 11381079 DOI: 10.1083/Jcb.153.5.917 |
0.303 |
|
| 2001 |
Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL, Moses HL. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism Molecular Biology of the Cell. 12: 27-36. PMID 11160820 DOI: 10.1091/Mbc.12.1.27 |
0.331 |
|
| 2001 |
McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International Journal of Cancer. 91: 76-82. PMID 11149423 DOI: 10.1002/1097-0215(20010101)91:1<76::Aid-Ijc1012>3.0.Co;2-8 |
0.706 |
|
| 2001 |
Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/ (B-2) signal transduction Seminars in Oncology. 28: 30-35. DOI: 10.1053/Sonc.2001.29722 |
0.305 |
|
| 2001 |
Arteaga CL, Chinratanalab W, Carter MB. Inhibitors of HER2/neu (erbB-2) signal transduction Seminars in Oncology. 28: 30-35. DOI: 10.1016/S0093-7754(01)90106-X |
0.43 |
|
| 2000 |
Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Research : Bcr. 2: 125-32. PMID 11250702 DOI: 10.1186/Bcr44 |
0.737 |
|
| 2000 |
Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. The Journal of Biological Chemistry. 275: 36803-10. PMID 10969078 DOI: 10.1074/Jbc.M005912200 |
0.442 |
|
| 2000 |
Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proceedings of the National Academy of Sciences of the United States of America. 97: 9609-14. PMID 10931950 DOI: 10.1073/Pnas.160564197 |
0.458 |
|
| 2000 |
Koli KM, Arteaga CL. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. Journal of Mammary Gland Biology and Neoplasia. 1: 373-80. PMID 10887511 DOI: 10.1007/Bf02017393 |
0.454 |
|
| 2000 |
Arteaga CL. Foundations of molecular therapies in breast carcinoma. Journal of Mammary Gland Biology and Neoplasia. 4: 333-5. PMID 10705917 DOI: 10.1023/A:1018710232077 |
0.364 |
|
| 2000 |
Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. The Journal of Biological Chemistry. 275: 6987-95. PMID 10702262 DOI: 10.1074/Jbc.275.10.6987 |
0.397 |
|
| 1999 |
Gobbi H, Dupont WD, Simpson JF, Plummer WD, Schuyler PA, Olson SJ, Arteaga CL, Page DL. Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. Journal of the National Cancer Institute. 91: 2096-101. PMID 10601380 DOI: 10.1093/Jnci/91.24.2096 |
0.455 |
|
| 1999 |
Srivastava DK, Husain I, Arteaga CL, Wilson SH. DNA polymerase beta expression differences in selected human tumors and cell lines. Carcinogenesis. 20: 1049-54. PMID 10357787 DOI: 10.1093/Carcin/20.6.1049 |
0.38 |
|
| 1999 |
Arteaga CL, Koli KM, Dugger TC, Clarke R. Reversal of Tamoxifen Resistance of Human Breast Carcinomas In Vivo by Neutralizing Antibodies to Transforming Growth Factor-β Journal of the National Cancer Institute. 91: 46-53. PMID 9890169 DOI: 10.1093/Jnci/91.1.46 |
0.415 |
|
| 1999 |
Ohmori T, Yang JL, Price JO, Arteaga CL. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research. 245: 350-9. PMID 9851876 DOI: 10.1006/Excr.1998.4261 |
0.431 |
|
| 1998 |
Ciardiello F, Dixit M, Di Isernia G, Damiano V, Bianco R, Bianco AR, Arteaga CL, Tortora G. Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector Breast Cancer Research and Treatment. 47: 57-62. PMID 9493976 DOI: 10.1023/A:1005909419828 |
0.509 |
|
| 1997 |
Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. The Journal of Biological Chemistry. 272: 23247-54. PMID 9287333 DOI: 10.1074/Jbc.272.37.23247 |
0.367 |
|
| 1997 |
Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells Journal of Biological Chemistry. 272: 8296-8302. PMID 9079651 DOI: 10.1074/Jbc.272.13.8296 |
0.388 |
|
| 1997 |
Dixit M, Yang JL, Poirier MC, Price JO, Andrews PA, Arteaga CL. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA Journal of the National Cancer Institute. 89: 365-373. PMID 9060958 DOI: 10.1093/Jnci/89.5.365 |
0.395 |
|
| 1997 |
Koli KM, Arteaga CL. Processing of the transforming growth factor beta type I and II receptors. Biosynthesis and ligand-induced regulation. The Journal of Biological Chemistry. 272: 6423-7. PMID 9045666 DOI: 10.1074/Jbc.272.10.6423 |
0.351 |
|
| 1996 |
Arteaga CL, Dugger TC, Hurd SD. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology. Breast Cancer Research and Treatment. 38: 49-56. PMID 8825122 DOI: 10.1007/Bf01803783 |
0.418 |
|
| 1996 |
Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nature Genetics. 12: 298-302. PMID 8589721 DOI: 10.1038/Ng0396-298 |
0.48 |
|
| 1996 |
Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M, Jensen RA. Growth Retardation and Tumour Inhibition by BRCA1 Obstetrical & Gynecological Survey. 51: 411-413. DOI: 10.1097/00006254-199607000-00014 |
0.309 |
|
| 1994 |
Johnson MD, Horiba M, Winnier AR, Arteaga CL. The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas. Human Pathology. 25: 146-53. PMID 8119714 DOI: 10.1016/0046-8177(94)90270-4 |
0.343 |
|
| 1993 |
Hernández-Sotomayor SM, Arteaga CL, Soler C, Carpenter G. Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity. Proceedings of the National Academy of Sciences of the United States of America. 90: 7691-7695. PMID 8102801 DOI: 10.1073/Pnas.90.16.7691 |
0.368 |
|
| 1993 |
Arteaga CL, Dugger TC, Winnier AR, Forbes JT. Evidence for a positive role of transforming growth factor‐β in human breast cancer cell tumorigenesis Journal of Cellular Biochemistry. 53: 187-193. PMID 8007696 DOI: 10.1002/Jcb.240531134 |
0.396 |
|
| 1993 |
Halter SA, Winnier AR, Arteaga CL. Pretreatment with vitamin A inhibits transforming growth factor alpha stimulation of human mammary carcinoma cells. Journal of Cellular Physiology. 156: 80-7. PMID 7686167 DOI: 10.1002/Jcp.1041560112 |
0.354 |
|
| 1993 |
Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. Journal of Clinical Investigation. 92: 2569-2576. PMID 7504687 DOI: 10.1172/Jci116871 |
0.448 |
|
| 1992 |
Arteaga CL, Coffey RJ. Transforming growth factor-beta isoforms in mammary neoplasia: more questions than answers. Human Pathology. 23: 1-3. PMID 1544663 DOI: 10.1016/0046-8177(92)90002-K |
0.316 |
|
| 1992 |
Arteaga CL. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Research and Treatment. 22: 101-6. PMID 1421419 DOI: 10.1007/Bf01833338 |
0.482 |
|
| 1991 |
Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. The Journal of Steroid Biochemistry and Molecular Biology. 37: 805-9. PMID 2178363 DOI: 10.1016/0960-0760(90)90423-I |
0.47 |
|
| 1991 |
Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America. 88: 10435-10439. PMID 1683701 DOI: 10.1073/Pnas.88.23.10435 |
0.373 |
|
| 1991 |
Arteaga CL, Osborne CK. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treatment and Research. 53: 289-304. PMID 1672083 DOI: 10.1007/978-1-4615-3940-7_14 |
0.488 |
|
| 1990 |
Osborne CK, Arteaga CL. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Research and Treatment. 15: 3-11. PMID 2183891 DOI: 10.1007/BF01811884 |
0.421 |
|
| 1989 |
Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 710-7. PMID 2715802 DOI: 10.1200/JCO.1989.7.6.710 |
0.36 |
|
| 1989 |
Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC, Allred DC, Osborne CK. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice Journal of Clinical Investigation. 84: 1418-1423. PMID 2553774 DOI: 10.1172/JCI114315 |
0.379 |
|
| 1988 |
Arteaga CL, Kisner DL, Goodman A, von Hoff DD. Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system. European Journal of Cancer & Clinical Oncology. 23: 1621-6. PMID 3428332 DOI: 10.1016/0277-5379(87)90440-8 |
0.341 |
|
| 1987 |
Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL, Von Hoff DD. Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. European Journal of Cancer & Clinical Oncology. 23: 545-51. PMID 3498632 DOI: 10.1016/0277-5379(87)90318-X |
0.325 |
|
| Show low-probability matches. |